Cover Page
Cover Page - shares | 6 Months Ended | |
Jul. 04, 2021 | Aug. 05, 2021 | |
Entity Listings [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jul. 4, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-5075 | |
Entity Registrant Name | PERKINELMER, INC | |
Entity Incorporation, State or Country Code | MA | |
Entity Tax Identification Number | 04-2052042 | |
Entity Address, Address Line One | 940 Winter Street, | |
Entity Address, City or Town | Waltham, | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02451 | |
City Area Code | 781 | |
Local Phone Number | 663-6900 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 112,114,149 | |
Entity Central Index Key | 0000031791 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --01-02 | |
PKI [Member] | ||
Entity Listings [Line Items] | ||
Trading Symbol | PKI | |
Trading Symbol | PKI | |
PKI 21A [Member] | ||
Entity Listings [Line Items] | ||
Trading Symbol | PKI 21A | |
Trading Symbol | PKI 21A | |
Common stock, $1 par value per share [Member] | ||
Entity Listings [Line Items] | ||
Title of 12(b) Security | Common stock, $1 par value per share | |
Title of 12(b) Security | Common stock, $1 par value per share | |
1.875% Notes due 2026 [Member] | ||
Entity Listings [Line Items] | ||
Title of 12(b) Security | 1.875% Notes due 2026 | |
Title of 12(b) Security | 1.875% Notes due 2026 | |
NEW YORK STOCK EXCHANGE, INC. [Member] | ||
Entity Listings [Line Items] | ||
Security Exchange Name | NYSE | |
Security Exchange Name | NYSE |
Condensed Consolidated Income S
Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Revenue from Contract with Customer, Excluding Assessed Tax | $ 1,228,471 | $ 811,718 | $ 2,536,160 | $ 1,464,114 |
Cost of Goods and Services Sold | 543,277 | 364,374 | 1,065,820 | 708,747 |
Selling, general and administrative expenses | 281,819 | 221,026 | 533,229 | 429,595 |
Research and development expenses | 65,824 | 49,521 | 126,040 | 98,435 |
Restructuring and other costs, net | 5,063 | 1,158 | 10,807 | 7,016 |
Operating income from continuing operations | 332,488 | 175,639 | 800,264 | 220,321 |
Interest And Other Expense Net | 6,431 | 10,812 | (6,275) | 20,805 |
Income from continuing operations before income taxes | 326,057 | 164,827 | 806,539 | 199,516 |
Provision for income taxes | 80,089 | 27,614 | 181,228 | 28,588 |
Income from continuing operations | 245,968 | 137,213 | 625,311 | 170,928 |
Loss on disposition of discontinued operations before income taxes | 0 | 0 | 0 | 0 |
Provision for income taxes on discontinued operations and dispositions | 38 | 51 | 76 | 101 |
Loss from discontinued operations and dispositions | (38) | (51) | (76) | (101) |
Net income | $ 245,930 | $ 137,162 | $ 625,235 | $ 170,827 |
Basic earnings (loss) per share: | ||||
Income (loss) from continuing operations (per share) | $ 2.20 | $ 1.23 | $ 5.58 | $ 1.54 |
Gain (loss) on discontinued operations and dispositions (per share) | 0 | 0 | 0 | 0 |
Net income (per share) | 2.20 | 1.23 | 5.58 | 1.54 |
Diluted earnings (loss) per share: | ||||
Income (loss) from continuing operations (per share) | 2.19 | 1.23 | 5.56 | 1.53 |
Gain (loss) on discontinued operations and dispositions (per share) | 0 | 0 | 0 | 0 |
Net income (per share) | $ 2.19 | $ 1.23 | $ 5.56 | $ 1.53 |
Weighted average shares of common stock outstanding: | ||||
Basic (in shares) | 111,973 | 111,329 | 112,000 | 111,225 |
Diluted (in shares) | 112,417 | 111,869 | 112,456 | 111,756 |
Cash dividends per common share | $ 0.07 | $ 0.07 | $ 0.14 | $ 0.14 |
Product [Member] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 767,759 | $ 601,506 | $ 1,579,311 | $ 1,027,035 |
Cost of Goods and Services Sold | 365,823 | 240,494 | 705,135 | 446,684 |
Service [Member] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 460,712 | 210,212 | 956,849 | 437,079 |
Cost of Goods and Services Sold | $ 177,454 | $ 123,880 | $ 360,685 | $ 262,063 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Common Stock Amount [Member] | Capital In Excess of Par Value [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] |
Beginning Balance at Dec. 29, 2019 | $ 2,813,824 | $ 111,140 | $ 90,357 | $ 2,811,973 | $ (199,646) |
Net income | 33,665 | 33,665 | |||
Dividends | (7,779) | (7,779) | |||
Exercise of employee stock options and related income tax benefits | 1,106 | 21 | 1,085 | ||
Issuance of common stock for employee benefit plans | (1,256) | (14) | (1,242) | 0 | 0 |
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | (6,342) | (66) | (6,276) | ||
Issuance of common stock for long-term incentive program | (3,028) | (197) | (2,831) | ||
Stock compensation | 997 | 0 | 997 | 0 | 0 |
Ending Balance at Apr. 05, 2020 | 2,759,746 | 111,306 | 90,236 | 2,836,531 | (278,327) |
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax | (78,681) | (78,681) | |||
Beginning Balance at Dec. 29, 2019 | 2,813,824 | 111,140 | 90,357 | 2,811,973 | (199,646) |
Net income | 170,827 | ||||
Other comprehensive income (loss) | (17,026) | ||||
Ending Balance at Jul. 05, 2020 | 2,967,463 | 111,501 | 106,744 | 2,965,890 | (216,672) |
Cumulative Effect of New Accounting Pronouncement in Period of Adoption | Accounting Standards Update 2016-02 [Member] | (1,328) | 0 | 0 | (1,328) | 0 |
Beginning Balance at Apr. 05, 2020 | 2,759,746 | 111,306 | 90,236 | 2,836,531 | (278,327) |
Net income | 137,162 | 137,162 | |||
Other comprehensive income (loss) | 61,655 | ||||
Dividends | (7,803) | (7,803) | |||
Exercise of employee stock options and related income tax benefits | 8,967 | 175 | 8,792 | ||
Issuance of common stock for employee benefit plans | (1,305) | (14) | (1,291) | 0 | 0 |
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | (327) | (4) | (323) | ||
Issuance of common stock for long-term incentive program | (5,125) | (2) | (5,123) | ||
Stock compensation | 1,633 | 8 | 1,625 | 0 | 0 |
Ending Balance at Jul. 05, 2020 | 2,967,463 | 111,501 | 106,744 | 2,965,890 | (216,672) |
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax | 61,655 | 61,655 | |||
Beginning Balance at Jan. 03, 2021 | 3,735,492 | 112,090 | 148,101 | 3,507,262 | (31,961) |
Net income | 379,305 | 379,305 | |||
Dividends | (7,846) | (7,846) | |||
Exercise of employee stock options and related income tax benefits | 4,987 | 95 | 4,892 | ||
Issuance of common stock for employee benefit plans | (8) | 0 | (8) | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | (42,779) | (295) | (42,484) | ||
Issuance of common stock for long-term incentive program | (4,450) | (176) | (4,274) | ||
Stock compensation | 899 | 0 | 899 | 0 | 0 |
Ending Balance at Apr. 04, 2021 | 4,002,305 | 112,066 | 115,690 | 3,878,721 | (104,172) |
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax | (72,211) | (72,211) | |||
Beginning Balance at Jan. 03, 2021 | 3,735,492 | 112,090 | 148,101 | 3,507,262 | (31,961) |
Net income | 625,235 | ||||
Other comprehensive income (loss) | (60,476) | ||||
Ending Balance at Jul. 04, 2021 | 4,239,807 | 112,025 | 103,394 | 4,116,825 | (92,437) |
Beginning Balance at Apr. 04, 2021 | 4,002,305 | 112,066 | 115,690 | 3,878,721 | (104,172) |
Net income | 245,930 | 245,930 | |||
Other comprehensive income (loss) | 11,735 | ||||
Dividends | (7,826) | (7,826) | |||
Exercise of employee stock options and related income tax benefits | 9,198 | 128 | 9,070 | ||
Issuance of common stock for employee benefit plans | (1,624) | (11) | (1,613) | ||
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | (30,145) | (209) | (29,936) | ||
Issuance of common stock for long-term incentive program | (5,022) | (24) | (4,998) | ||
Stock compensation | 1,964 | 5 | 1,959 | 0 | 0 |
Ending Balance at Jul. 04, 2021 | 4,239,807 | $ 112,025 | $ 103,394 | $ 4,116,825 | (92,437) |
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax | $ 11,735 | $ 11,735 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Net income | $ 245,930 | $ 137,162 | $ 625,235 | $ 170,827 |
Other Comprehensive Income (Loss), Net of Tax [Abstract] | ||||
Foreign currency translation adjustments, net of income taxes | 11,724 | 61,568 | (60,581) | (17,025) |
Unrealized gain (loss) on securities, net of income taxes | 11 | 87 | 105 | (1) |
Other comprehensive income (loss) | 11,735 | 61,655 | (60,476) | (17,026) |
Comprehensive income | $ 257,665 | $ 198,817 | $ 564,759 | $ 153,801 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jul. 04, 2021 | Jan. 03, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 572,810 | $ 402,036 |
Accounts receivable, net | 992,602 | 1,155,109 |
Inventories | 513,429 | 514,567 |
Other current assets | 181,151 | 167,208 |
Total current assets | 2,259,992 | 2,238,920 |
Property, plant and equipment, net: | ||
Property, plant and equipment, net | 379,065 | 368,304 |
Operating Lease, Right-of-Use Asset | 208,494 | 207,236 |
Intangible assets, net | 1,561,534 | 1,365,693 |
Goodwill | 3,844,070 | 3,447,114 |
Other assets, net | 486,306 | 333,048 |
Total assets | 8,739,461 | 7,960,315 |
Current liabilities: | ||
Current portion of long-term debt | 4,669 | 380,948 |
Accounts payable | 324,711 | 327,325 |
Accrued expenses and other current liabilities | 793,443 | 943,916 |
Total current liabilities | 1,122,823 | 1,652,189 |
Long-term debt | 2,348,523 | 1,609,701 |
Long-term liabilities | 838,974 | 774,531 |
Operating Lease, Liability, Noncurrent | 189,334 | 188,402 |
Total liabilities | 4,499,654 | 4,224,823 |
Commitments and contingencies (see Note 14) | ||
Stockholders' equity: | ||
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | 0 | 0 |
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,025,000 shares and 112,090,000 shares at July 4, 2021 and January 3, 2021, respectively | 112,025 | 112,090 |
Capital in excess of par value | 103,394 | 148,101 |
Retained earnings | 4,116,825 | 3,507,262 |
Accumulated other comprehensive loss | (92,437) | (31,961) |
Total stockholders’ equity | 4,239,807 | 3,735,492 |
Total liabilities and stockholders’ equity | $ 8,739,461 | $ 7,960,315 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Jul. 04, 2021 | Jan. 03, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 1 | $ 1 |
Preferred stock, authorized | 1,000,000 | 1,000,000 |
Preferred stock, issued | 0 | 0 |
Preferred stock, outstanding | 0 | 0 |
Common stock, par value | $ 1 | $ 1 |
Common stock, authorized | 300,000,000 | 300,000,000 |
Common stock, issued | 112,025,000 | 112,090,000 |
Common stock, outstanding | 112,025,000 | 112,090,000 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Operating activities: | ||||
Net income | $ 245,930 | $ 137,162 | $ 625,235 | $ 170,827 |
Loss from discontinued operations and dispositions, net of income taxes | 38 | 51 | 76 | 101 |
Income from continuing operations | 245,968 | 137,213 | 625,311 | 170,928 |
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations: | ||||
Restructuring and other costs, net | 5,063 | 1,158 | 10,807 | 7,016 |
Depreciation and amortization | 145,822 | 120,047 | ||
Loss (Gain) on disposition of businesses and assets, net | 485 | |||
Loss (Gain) on Disposition of Assets, net | 0 | |||
Stock-based compensation | 12,361 | 12,654 | ||
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | 477 | (11,446) | ||
Amortization of deferred debt financing costs and accretion of discounts | 1,724 | 1,642 | ||
Change in fair value of financial securities | (8,633) | 0 | (27,931) | 0 |
Amortization of acquired inventory revaluation | 5,303 | 1,485 | ||
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested: | ||||
Accounts receivable, net | 155,270 | 4,312 | ||
Inventories | 7,239 | (126,707) | ||
Accounts payable | (26,795) | 20,907 | ||
Accrued expenses and other | (148,226) | (2,677) | ||
Net cash provided by operating activities | 761,362 | 198,646 | ||
Investing activities: | ||||
Capital expenditures | (34,675) | (37,138) | ||
Proceeds from surrender of life insurance policies | 0 | 131 | ||
Payments to Acquire Investments | (14,507) | (7,393) | ||
Proceeds from Divestiture of Businesses | 0 | 1,815 | ||
Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired | (702,697) | (2,990) | ||
Net cash used in investing activities | (751,879) | (45,575) | ||
Financing activities: | ||||
Payments of borrowings | 763,545 | 290,000 | ||
Proceeds from borrowings | 729,000 | 188,000 | ||
Repayments of Senior Debt | (339,605) | 0 | ||
Proceeds from sale of senior debt | 799,856 | 0 | ||
Payments of debt financing costs | (8,242) | 0 | ||
Settlement of cash flow hedges | (5,935) | 5,037 | ||
Net payments on other credit facilities | (11,826) | (6,036) | ||
Payments for acquisition-related contingent consideration | 0 | (5,200) | ||
Proceeds from issuance of common stock under stock plans | 14,185 | 10,074 | ||
Purchases of common stock | (72,924) | (6,669) | ||
Dividends paid | (15,697) | (15,572) | ||
Net cash provided by (used in) financing activities | 325,267 | (120,366) | ||
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | (10,659) | (4,658) | ||
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent | 324,091 | 28,047 | ||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period | 402,613 | 191,894 | ||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period | 726,704 | 219,941 | 726,704 | 219,941 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] | ||||
Cash and cash equivalents | 572,810 | 218,536 | 572,810 | 218,536 |
Restricted Cash, Current | 1,750 | 1,405 | 1,750 | 1,405 |
Restricted Cash, Noncurrent | 152,144 | 0 | 152,144 | 0 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $ 726,704 | $ 219,941 | $ 726,704 | $ 219,941 |
Basis of Presentation
Basis of Presentation | 6 Months Ended |
Jul. 04, 2021 | |
Accounting Policies [Abstract] | |
Basis of Accounting [Text Block] | Basis of Presentation The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended January 3, 2021, filed with the SEC (the “2020 Form 10-K”). The balance sheet amounts at January 3, 2021 in this report were derived from the Company’s audited 2020 consolidated financial statements included in the 2020 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended July 4, 2021 and July 5, 2020, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 2, 2022 ("fiscal year 2021") will include 52 weeks, and the fiscal year ended January 3, 2021 ("fiscal year 2020") included 53 weeks. Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim p eriods within those years. In accordance with ASU 2019-12, the Company adopted the guidance beginning on January 4, 2021. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. |
Revenue (Notes)
Revenue (Notes) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer [Text Block] | Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue. Reportable Segments Three Months Ended July 4, 2021 July 5, 2020 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 206,938 $ 368,365 $ 575,303 $ 160,382 $ 156,609 $ 316,991 Europe 145,576 200,777 346,353 103,497 149,867 253,364 Asia 160,315 146,500 306,815 127,123 114,240 241,363 $ 512,829 $ 715,642 $ 1,228,471 $ 391,002 $ 420,716 $ 811,718 Primary end-markets Diagnostics $ — $ 715,642 $ 715,642 $ — $ 420,716 $ 420,716 Life sciences 308,681 — 308,681 237,120 — 237,120 Applied markets 204,148 — 204,148 153,882 — 153,882 $ 512,829 $ 715,642 $ 1,228,471 $ 391,002 $ 420,716 $ 811,718 Timing of revenue recognition Products and services transferred at a point in time $ 378,310 $ 506,603 $ 884,913 $ 265,903 $ 398,646 $ 664,549 Services transferred over time 134,519 209,039 343,558 125,099 22,070 147,169 $ 512,829 $ 715,642 $ 1,228,471 $ 391,002 $ 420,716 $ 811,718 Reportable Segments Six Months Ended July 4, 2021 July 5, 2020 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 382,053 $ 769,292 $ 1,151,345 $ 329,498 $ 261,766 $ 591,264 Europe 281,034 512,520 793,554 222,154 231,466 453,620 Asia 304,351 286,910 591,261 237,745 181,485 419,230 $ 967,438 $ 1,568,722 $ 2,536,160 $ 789,397 $ 674,717 $ 1,464,114 Primary end-markets Diagnostics $ — $ 1,568,722 $ 1,568,722 $ — $ 674,717 $ 674,717 Life sciences 585,882 — 585,882 482,853 — 482,853 Applied markets 381,556 — 381,556 306,544 — 306,544 $ 967,438 $ 1,568,722 $ 2,536,160 $ 789,397 $ 674,717 $ 1,464,114 Timing of revenue recognition Products and services transferred at a point in time $ 704,972 $ 1,121,709 $ 1,826,681 $ 533,810 $ 630,299 $ 1,164,109 Services transferred over time 262,466 447,013 709,479 255,587 44,418 300,005 $ 967,438 $ 1,568,722 $ 2,536,160 $ 789,397 $ 674,717 $ 1,464,114 Major Customer Concentration Revenues from one customer in the Company's Diagnostics segment represent approximately $192.5 million and $398.0 million of the Company's total revenue for the three and six months ended July 4, 2021. Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets. The balance of contract assets as of July 4, 2021 and January 3, 2021 were $51.9 million and $59.5 million, respectively. The amount of unbilled receivables recognized at the beginning of the period that were transferred to trade receivables during the six months ended July 4, 2021 was $46.2 million. The increase in unbilled receivables during the six months ended July 4, 2021 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $38.6 million. Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or "Accrued expenses and other current liabilities" or as long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The balance of contract liabilities as of July 4, 2021 and January 3, 2021 were $230.7 million and $238.1 million, respectively. The increase in contract liabilities during the six months ended July 4, 2021 due to cash received, excluding amounts recognized as revenue during the period, was $49.6 million. The amount of revenue recognized during the six months ended July 4, 2021 that was included in the contract liability balance at the beginning of the period was $57.1 million. Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheets. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities. Transaction price allocated to the remaining performance obligations | |||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 1,228,471 | $ 811,718 | $ 2,536,160 | $ 1,464,114 |
Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 884,913 | 664,549 | 1,826,681 | 1,164,109 |
Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 343,558 | 147,169 | 709,479 | 300,005 |
Americas [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 575,303 | 316,991 | 1,151,345 | 591,264 |
Europe [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 346,353 | 253,364 | 793,554 | 453,620 |
Asia [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 306,815 | 241,363 | 591,261 | 419,230 |
Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 |
Life Sciences [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 308,681 | 237,120 | 585,882 | 482,853 |
Applied Markets [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 204,148 | 153,882 | 381,556 | 306,544 |
Discovery & Analytical Solutions [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 512,829 | 391,002 | 967,438 | 789,397 |
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 378,310 | 265,903 | 704,972 | 533,810 |
Discovery & Analytical Solutions [Member] | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 134,519 | 125,099 | 262,466 | 255,587 |
Discovery & Analytical Solutions [Member] | Americas [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 206,938 | 160,382 | 382,053 | 329,498 |
Discovery & Analytical Solutions [Member] | Europe [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 145,576 | 103,497 | 281,034 | 222,154 |
Discovery & Analytical Solutions [Member] | Asia [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 160,315 | 127,123 | 304,351 | 237,745 |
Discovery & Analytical Solutions [Member] | Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Discovery & Analytical Solutions [Member] | Life Sciences [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 308,681 | 237,120 | 585,882 | 482,853 |
Discovery & Analytical Solutions [Member] | Applied Markets [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 204,148 | 153,882 | 381,556 | 306,544 |
Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 |
Diagnostics [Member] | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 506,603 | 398,646 | 1,121,709 | 630,299 |
Diagnostics [Member] | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 209,039 | 22,070 | 447,013 | 44,418 |
Diagnostics [Member] | Americas [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 368,365 | 156,609 | 769,292 | 261,766 |
Diagnostics [Member] | Europe [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 200,777 | 149,867 | 512,520 | 231,466 |
Diagnostics [Member] | Asia [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 146,500 | 114,240 | 286,910 | 181,485 |
Diagnostics [Member] | Diagnostics [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 |
Diagnostics [Member] | Life Sciences [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 |
Diagnostics [Member] | Applied Markets [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 | $ 0 | $ 0 | $ 0 |
Business Combinations
Business Combinations | 6 Months Ended |
Jul. 04, 2021 | |
Business Combinations [Abstract] | |
Business Combinations | Business Combinations Acquisitions in fiscal year 2021 During the first six months of fiscal year 2021, the Company completed the acquisition of three businesses for aggregate consideration of $860.5 million. The acquired businesses include Oxford Immunotec Global PLC ("Oxford"), a company based in Abingdon, UK with approximately 275 employees, for a total consideration of $590.9 million, Nexcelom Bioscience Holdings, LLC ("Nexcelom"), a company based in Lawrence, Massachusetts with approximately 130 employees, for a total consideration of $267.1 million, and one other business, which was acquired for a total consideration of $2.5 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. Identifiable definite-lived intangible assets, such as core technology, trade names, and customer relationships, acquired as part of these acquisitions had a weighted average amortization period of 11.9 years. The total purchase price for the acquisitions in fiscal year 2021 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary (In thousands) Fair value of business combination: Cash payments $ 859,548 Other liability 910 Less: cash acquired (157,278) Total $ 703,180 Identifiable assets acquired and liabilities assumed: Current assets $ 35,265 Property, plant and equipment 13,293 Other assets 15,187 Identifiable intangible assets: Core technology 193,260 Trade names 26,070 Patents 150 Customer relationships 104,270 Goodwill 428,923 Deferred taxes (68,821) Liabilities assumed (44,417) Total $ 703,180 During the second quarter of fiscal year 2021, the Company entered into an agreement to acquire SIRION Biotech GmbH ("Sirion"), a leading, global provider of viral vector-based technologies headquartered in Munich, Germany with approximately 50 employees that drive improved delivery performance for cell and gene therapies. The total consideration is approximately $94.8 million (€80.0 million) in cash and a potential obligation to pay the shareholders of Sirion additional contingent consideration of up to $85.3 million (€72.0 million). The acquisition is expected to close during the third quarter of fiscal year 2021. Subsequent to July 4, 2021, the Company completed the acquisition of Immunodiagnostic Systems Holdings PLC, a company headquartered in Boldon, the United Kingdom, for a total consideration of approximately $155.0 million (£110.0 million) in cash. The operations for this acquisition will be reported within the results of the Company's Diagnostics segment from the acquisition date. Subsequent to July 4, 2021, the Company entered into an agreement to acquire BioLegend, Inc. ("BioLegend"), a leading, global provider of life science antibodies and reagents headquartered in San Diego, California with approximately 700 employees, for approximately $5.25 billion in a combination of cash and stock, subject to certain adjustments. The operations for this acquisition will be reported within the results of the Company's Discovery & Analytical Solutions segment from the acquisition date. The acquisition is expected to close by the end of fiscal year 2021, subject to regulatory approvals and other customary closing conditions. Acquisitions in fiscal year 2020 During the fiscal year 2020, the Company completed the acquisition of four businesses for aggregate consideration of $438.9 million. The acquired businesses were Horizon Discovery Group plc (“Horizon”), a company based in Cambridge, UK with approximately 400 employees, which was acquired on December 23, 2020 for a total consideration of $399.8 million (£296.0 million), and three other businesses, which were acquired for a total consideration of $39.1 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. Identifiable definite-lived intangible assets, such as core technology, trade names, customer relationships and in-process research and development, acquired as part of these acquisitions had a weighted average amortization period of 11.0 years. The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary (In thousands) Fair value of business combination: Cash payments $ 437,661 Other liability 1,660 Working capital and other adjustments (384) Less: cash acquired (26,840) Total $ 412,097 Identifiable assets acquired and liabilities assumed: Current assets $ 35,532 Property, plant and equipment 20,302 Other assets 18,114 Identifiable intangible assets: Core technology 65,730 Trade names 5,580 Customer relationships 108,523 Goodwill 221,960 Deferred taxes (27,142) Deferred revenue (2,031) Liabilities assumed (45,171) Total $ 412,097 The preliminary allocations of the purchase prices for acquisitions are based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. The allocations of the purchase prices for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. As of July 4, 2021, the Company may have to pay contingent consideration related to acquisitions with open contingency periods of up to $7.2 million. As of July 4, 2021, the Company has recorded contingent consideration obligations of $3.3 million, of which $3.2 million was recorded in accrued expenses and other current liabilities, and $0.1 million was recorded in long-term liabilities. As of January 3, 2021, the Company had recorded contingent consideration obligations with an estimated fair value of $3.0 million, of which $2.9 million was recorded in accrued expenses and other current liabilities, and $0.1 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 1.5 years from July 4, 2021, and the remaining weighted average expected earnout period at July 4, 2021 was 0.8 years. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. Total acquisition and divestiture-related costs for the three and six months ended July 4, 2021 were $10.6 million and $15.1 million, respectively. These amounts included $6.3 million and $11.7 million of incentive award associated with the Company's acquisition of Meizheng Group for the three and six months ended July 4, 2021, respectively. Net foreign exchange gain and interest expense related to the Company's acquisition of Oxford for the six months ended July 4, 2021 amounted to $5.4 million and $0.2 million, respectively. Total acquisition and divestiture-related costs (gains) for the three and six months ended July 5, 2020 were $(5.2) million and $7.1 million, respectively. These amounts included $(5.6) million and $6.7 million of incentive award associated with the Company's acquisition of Meizheng Group for the three and six months ended July 5, 2020, respectively. These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other expense, net in the Company's consolidated statements of operations. |
Restructuring and Lease Charges
Restructuring and Lease Charges, Net | 6 Months Ended |
Jul. 04, 2021 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Lease Charges, Net | Restructuring and Other Costs, Net The Company implemented restructuring plans in the first and second quarters of fiscal year 2021 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives and integrate new acquisitions (the "Q1 2021 Plan" and "Q2 2021 Plan", respectively). The Company implemented a restructuring plan in the third quarter of fiscal year 2020 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q3 2020 Plan"). The Company implemented a restructuring plan in the first quarter of fiscal year 2020 consisting of workforce reductions and closure of excess facilities principally intended to realign resources to emphasize growth initiatives (the "Q1 2020 Plan"). Details of the plans initiated in previous years (the “Previous Plans”) are discussed more fully in Note 5 to the audited consolidated financial statements in the 2020 Form 10-K. The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2021 and 2020 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q2 2021 Plan 25 $ 968 $ 564 $ — $ — $ 1,532 Q1 FY2022 — Q1 2021 Plan 77 3,941 1,615 — — 5,556 Q4 FY2021 — Q3 2020 Plan 23 2,080 901 — — 2,981 Q2 FY2021 — Q1 2020 Plan 32 2,312 1,134 92 682 4,220 Q4 FY2020 Q1 FY2022 The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded net pre-tax charges of $0.4 million and $0.7 million in the Discovery & Analytical Solutions segment and Diagnostics segment, respectively, during each of the three and six months ended July 4, 2021 as a result of these contract terminations. The Company recorded pre-tax charges of $2.3 million and $2.5 million associated with relocating facilities during the three and six months ended July 4, 2021, respectively, in the Discovery & Analytical Solutions segment. The Company recorded pre-tax charges of $0.2 million associated with relocating facilities during each of the three and six months ended July 4, 2021, in the Diagnostics segment. The Company expects to make payments on these relocation activities through end of fiscal year 2022. |
Interest and Other Expense (Inc
Interest and Other Expense (Income), Net | 6 Months Ended |
Jul. 04, 2021 | |
Other Income and Expenses [Abstract] | |
Interest and Other Expense (Income), Net | Interest and Other Expense, Net Interest and other expense, net, consisted of the following: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Interest income $ (367) $ (192) $ (778) $ (457) Interest expense 16,750 11,586 30,876 25,251 Change in fair value of financial securities (8,633) — (27,931) — Other income, net (1,319) (582) (8,442) (3,989) Total interest and other (income) expense, net $ 6,431 $ 10,812 $ (6,275) $ 20,805 Foreign currency transaction (gains) losses were $(0.8) million and $0.6 million for the three and six months ended July 4, 2021, respectively. Foreign currency transaction (gains) losses were $(6.4) million and $3.5 million for the three and six months ended July 5, 2020, respectively. Net losses (gains) from forward currency hedge contracts were $3.3 million and $(1.5) million for the three and six months ended July 4, 2021, respectively. Net losses (gains) from forward currency hedge contracts were $7.6 million and $(4.0) million for the three and six months ended July 5, 2020, respectively. |
Inventories, Net
Inventories, Net | 6 Months Ended |
Jul. 04, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories, Net | Inventories Inventories consisted of the following: July 4, January 3, (In thousands) Raw materials $ 199,770 $ 205,022 Work in progress 40,646 35,160 Finished goods 273,013 274,385 Total inventories $ 513,429 $ 514,567 |
Debt
Debt | 6 Months Ended |
Jul. 04, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt The Company’s debt consisted of the following: July 4, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ 125,000 $ — $ (2,264) $ 122,736 1.875% Senior Unsecured Notes due in 2026 ("2026 Notes") 592,300 (2,904) (2,531) 586,865 3.3% Senior Unsecured Notes due in 2029 ("2029 Notes") 850,000 (2,368) (6,556) 841,076 2.55% Senior Unsecured Notes due in 2031 400,000 (136) (3,563) 396,301 3.625% Senior Unsecured Notes due in 2051 400,000 (4) (4,545) 395,451 Other Debt Facilities, non-current 6,094 — — 6,094 Total Long-Term Debt $ 2,373,394 $ (5,412) $ (19,459) $ 2,348,523 Current Portion of Long-term Debt: Other Debt Facilities, current 4,669 — — 4,669 Total $ 2,378,063 $ (5,412) $ (19,459) $ 2,353,192 January 3, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ 158,595 $ — $ (2,621) $ 155,974 2026 Notes 610,750 (3,253) (2,782) 604,715 2029 Notes 850,000 (2,496) (6,908) 840,596 Other Debt Facilities, non-current 8,416 — — 8,416 Total Long-Term Debt $ 1,627,761 $ (5,749) $ (12,311) $ 1,609,701 Current Portion of Long-term Debt: 0.6% Senior Unsecured Notes due in 2021 ("2021 Notes") 366,450 (16) (229) 366,205 Other Debt Facilities, current 14,743 — — 14,743 Total $ 2,008,954 $ (5,765) $ (12,540) $ 1,990,649 2.55% Senior Unsecured Notes due in 2031. On March 8, 2021, the Company issued $400.0 million aggregate principal amount of senior unsecured notes due in 2031 (the "2031 Notes”) in a registered public offering and received $399.9 million of net proceeds from the issuance. The 2031 Notes were issued at 99.965% of the principal amount, which resulted in a discount of $0.1 million. As of July 4, 2021, the 2031 Notes had an aggregate carrying value of $396.3 million, net of $0.1 million of unamortized original issue discount and $3.6 million of unamortized debt issuance costs. The 2031 Notes mature in March 2031 and bear interest at an annual rate of 2.55%. Interest on the 2031 Notes is payable semi-annually on March 15th and September 15th each year. Prior to December 15, 2030 (three months prior to their maturity date), the Company may redeem the 2031 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2031 Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that the 2031 Notes matured on December 15, 2030, discounted to the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2031 Notes) plus 15 basis points, plus accrued and unpaid interest thereon to, but excluding, the date of redemption. At any time on or after December 15, 2030, the Company may redeem the 2031 Notes, in whole or in part, at the Company’s option, at a redemption price equal to 100% of the principal amount of the 2031 Notes due to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Upon a change of control repurchase event (as defined in the indenture governing the 2031 Notes) of the Company, the Company will, in certain circumstances, make an offer to repurchase the 2031 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest, if any, to, but excluding, the date of repurchase. 3.625% Senior Unsecured Notes due in 2051. On March 8, 2021, the Company issued $400.0 million aggregate principal amount of senior unsecured notes due in 2051 (the "2051 Notes”) in a registered public offering and received $400.00 million of net proceeds from the issuance. The 2051 Notes were issued at 99.999% of the principal amount, which resulted in a discount of $4,000. As of July 4, 2021, the 2051 Notes had an aggregate carrying value of $395.5 million, net of $4,000 of unamortized original issue discount and $4.5 million of unamortized debt issuance costs. The 2051 Notes mature in March 2051 and bear interest at an annual rate of 3.625%. Interest on the 2051 Notes is payable semi-annually on March 15th and September 15th each year. Prior to September 15, 2050 (six months prior to their maturity date), the Company may redeem the 2051 Notes in whole at any time or in part from time to time, at its option, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2051 Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued but unpaid as of the date of redemption) assuming that the 2051 Notes matured on September 15, 2050, discounted to the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the indenture governing the 2051 Notes) plus 20 basis points, plus accrued and unpaid interest thereon to, but excluding, the date of redemption. At any time on or after September 15, 2050, the Company may redeem the 2051 Notes, in whole or in part, at the Company’s option, at a redemption price equal to 100% of the principal amount of the 2051 Notes due to be redeemed plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Upon a change of control repurchase event (as defined in the indenture governing the 2051 Notes) of the Company, the Company will, in certain circumstances, make an offer to repurchase the 2051 Notes at a price equal to 101% of their principal amount plus any accrued and unpaid interest, if any, to, but excluding, the date of repurchase. |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Jul. 04, 2021 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Number of common shares—basic 111,973 111,329 112,000 111,225 Effect of dilutive securities: Stock options 344 470 352 475 Restricted stock awards 100 70 104 56 Number of common shares—diluted 112,417 111,869 112,456 111,756 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 224 390 193 440 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future. |
Industry Segment Information
Industry Segment Information | 6 Months Ended |
Jul. 04, 2021 | |
Segment Reporting [Abstract] | |
Industry Segment Information | Industry Segment InformationThe Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2020 Form 10-K. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Discovery & Analytical Solutions Product revenue $ 318,085 $ 225,617 $ 585,340 $ 440,973 Service revenue 194,744 165,385 382,098 348,424 Total revenue 512,829 391,002 967,438 789,397 Operating income from continuing operations 64,155 39,430 107,102 67,943 Diagnostics Product revenue 449,674 375,889 993,971 586,062 Service revenue 265,968 44,827 574,751 88,655 Total revenue 715,642 420,716 1,568,722 674,717 Operating income from continuing operations 286,280 160,300 727,747 189,891 Corporate Operating loss from continuing operations (17,947) (24,091) (34,585) (37,513) Continuing Operations Product revenue 767,759 601,506 1,579,311 1,027,035 Service revenue 460,712 210,212 956,849 437,079 Total revenue 1,228,471 811,718 2,536,160 1,464,114 Operating income from continuing operations 332,488 175,639 800,264 220,321 Interest and other expense (income), net (see Note 5) 6,431 10,812 (6,275) 20,805 Income from continuing operations before income taxes $ 326,057 $ 164,827 $ 806,539 $ 199,516 |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jul. 04, 2021 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: July 4, January 3, (In thousands) Foreign currency translation adjustments, net of income taxes $ (91,518) $ (30,937) Unrecognized prior service costs, net of income taxes (747) (747) Unrealized net losses on securities, net of income taxes (172) (277) Accumulated other comprehensive loss $ (92,437) $ (31,961) Stock Repurchases: On July 31, 2020, the Company's Board of Directors (the "Board") authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on July 27, 2022 unless terminated earlier by the Board and may be suspended or discontinued at any time. During the three months ended July 4, 2021, the Company repurchased 200,000 shares of common stock under the Repurchase Program for an aggregate cost of $29.0 million. During the six months ended July 4, 2021, the Company repurchased 433,000 shares of common stock under the Repurchase Program for an aggregate cost of $62.6 million. As of July 4, 2021, $187.4 million remained available for aggregate repurchases of shares under the Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the three months ended July 4, 2021, the Company repurchased 8,622 shares of common stock for this purpose at an aggregate cost of $1.2 million. During the six months ended July 4, 2021, the Company repurchased 70,413 shares of common stock for this purpose at an aggregate cost of $10.3 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quarters of fiscal year 2021 and in each quarter of fiscal year 2020. At July 4, 2021, the Company had accrued $7.9 million for dividends declared on April 29, 2021 for the second quarter of fiscal year 2021 that were paid on August 6, 2021. On July 23, 2021, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2021 that will be payable in November 2021. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resou rces. |
Stock Plans
Stock Plans | 6 Months Ended |
Jul. 04, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock Plans | Stock Plans The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three and six months ended July 4, 2021 and July 5, 2020: Three Months Ended July 4, July 5, (In thousands) Cost of revenue $ 692 $ 253 Research and development expenses 366 316 Selling, general and administrative expenses 6,146 9,034 Total stock-based compensation expense $ 7,204 $ 9,603 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $4.1 million and $2.2 million for the three and six months ended July 4, 2021 and July 5, 2020, respectively. Stock-based compensation costs capitalized as part of inventory were $0.5 million and $0.3 million as of July 4, 2021 and July 5, 2020, respectively. Stock Options : The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three and Six Months Ended July 4, July 5, Risk-free interest rate 0.6 % 0.9 % Expected dividend yield 0.2 % 0.3 % Expected term 5 years 5 years Expected stock volatility 27.3 % 23.8 % The following table summarizes stock option activity for the six months ended July 4, 2021: Number Weighted- Weighted-Average Total (In thousands) (In years) (In millions) Outstanding at January 3, 2021 961 $ 74.40 Granted 162 134.53 Exercised (96) 53.98 Forfeited (7) 88.54 Outstanding at July 4, 2021 1,020 $ 85.78 4.3 $ 46.2 Exercisable at July 4, 2021 640 $ 72.63 3.2 $ 36.7 The weighted-average per-share grant-date fair value of options granted during the six months ended July 4, 2021 and July 5, 2020 was $65.80 and $18.98. The total intrinsic value of options exercised during the three and six months ended July 4, 2021 and July 5, 2020 was $9.5 million and $7.8 million, respectively. Cash received from option exercises for the six months ended July 4, 2021 and July 5, 2020 was $5.0 million and $1.1 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $0.9 million and $0.8 million for the three and six months ended July 4, 2021 and July 5, 2020, respectively. There was $8.9 million of total unrecognized compensation cost related to nonvested stock options granted as of July 4, 2021. This cost is expected to be recognized over a weighted-average period of 2.3 years. Restricted Stock Awards : The following table summarizes restricted stock award activity for the six months ended July 4, 2021: Number of Weighted- (In thousands) Nonvested at January 3, 2021 296 $ 85.67 Granted 102 129.27 Vested (102) 83.16 Forfeited (5) 86.90 Nonvested at July 4, 2021 291 $ 101.83 The fair value of restricted stock awards vested during the three and six months ended July 4, 2021 and July 5, 2020 was $8.5 million and $1.4 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $2.8 million and $2.7 million for the three and six months ended July 4, 2021 and July 5, 2020, respectively. As of July 4, 2021, there was $23.4 million of total unrecognized compensation cost related to nonvested restricted stock awards. This cost is expected to be recognized over a weighted-average period of 1.8 years. Performance Restricted Stock Units: As part of the Company's executive compensation program, the Company granted 77,373 performance restricted stock units during the six months ended July 4, 2021 that will vest based on performance of the Company. The weighted-average per-share grant date fair value of performance restricted stock units granted during the six months ended July 4, 2021 was $113.44. During the six months ended July 4, 2021, no performance restricted stock units were forfeited. The total compensation expense recognized related to performance restricted stock units was $1.4 million and $2.0 million for the three and six months ended July 4, 2021 and July 5, 2020, respectively. As of July 4, 2021, there were 128,386 performance restricted stock units outstanding. Performance Units : No performance units were granted during the six months ended July 4, 2021. During the six months ended July 4, 2021, no performance units were forfeited. The total compensation expense (income) recognized related to performance units was $0.1 million and $3.3 million for the three and six months ended July 4, 2021 and July 5, 2020, respectively. As of July 4, 2021, there were no performance units outstanding. Stock Awards : The Company’s stock award program provides an annual equity award to non-employee directors. During the six months ended July 4, 2021, the Company awarded no shares to non-employee directors. The total compensation expense recognized related to the stock awards were minimal for the six months ended July 5, 2020. Employee Stock Purchase Plan : During the six months ended July 4, 2021, the Company issued 58 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $136.33 per share. During the six months ended July 5, 2020, the Company issued 13,612 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $92.25 per share. At July 4, 2021, an aggregate of 0.8 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan. |
Goodwill and Intangible Assets,
Goodwill and Intangible Assets, Net | 6 Months Ended |
Jul. 04, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill . The Company performed its annual impairment testing for its reporting units as of January 4, 2021, its annual impairment testing date for fiscal year 2021. The Company concluded that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20% for each reporting unit, except for the Company's Tulip reporting unit which had a fair value that was between 10% and 20% more than its carrying value. The range of the long-term terminal growth rates for the Compa ny’s reporting units was 3% to 5% for the fiscal year 2021 impairment analysis. The range for the discount rates for the reporting units was 8.0% to 12.5%. Keeping all other variables constant, a 10% change in any one of these input assumptions for the various reporting units, except for the Tulip reporting unit, would still allow the Company to conclude that there was no impairment of goodwill. As of January 4, 2021, the Company's Tulip reporting unit, which had a goodwill balance of $77.8 million, was at increased risk of an impairment charge given its ongoing weakness due to the impact of COVID-19. Despite the increased risk associated with this reporting unit, the Company does not currently expect a significant change in the key estimates or assumptions driving the fair value of this reporting unit that would lead to a material impairment charge. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. Non-amortizing intangibles are also subject to an annual impairment test. The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of the amortizing intangible asset. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible asset at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful life of the Company's non-amortizing intangible asset is no longer indefinite, the asset will be tested for impairment. This intangible asset will then be amortized prospectively over its estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 4, 2021 and concluded that there was no impairment of its non-amortizing intangible asset. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first six months of fiscal year 2021. The changes in the carrying amount of goodwill for the six months ended July 4, 2021 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at January 3, 2021 $ 1,755,887 $ 1,691,227 $ 3,447,114 Foreign currency translation (19,151) (17,806) (36,957) Acquisitions, earn-outs and other 155,199 278,714 433,913 Balance at July 4, 2021 $ 1,891,935 $ 1,952,135 $ 3,844,070 Identifiable intangible asset balances by category were as follows: July 4, January 3, (In thousands) Patents $ 31,042 $ 30,855 Less: Accumulated amortization (28,590) (28,440) Net patents 2,452 2,415 Trade names and trademarks 122,959 98,661 Less: Accumulated amortization (54,468) (48,806) Net trade names and trademarks 68,491 49,855 Licenses 59,015 58,700 Less: Accumulated amortization (53,391) (52,452) Net licenses 5,624 6,248 Core technology 980,388 789,799 Less: Accumulated amortization (435,709) (398,992) Net core technology 544,679 390,807 Customer relationships 1,441,419 1,357,660 Less: Accumulated amortization (582,624) (522,820) Net customer relationships 858,795 834,840 In-process research and development 10,909 10,944 Net amortizable intangible assets 1,490,950 1,295,109 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,561,534 $ 1,365,693 Total amortization expense related to definite-lived intangible assets was $59.6 million and $113.7 million for the three and six months ended July 4, 2021, respectively, and $46.7 million and $94.0 million for the three and six months ended July 5, 2020, respectively. Estimated amortization expense related to amortizable intangible assets for each of the next five |
Warranty Reserves
Warranty Reserves | 6 Months Ended |
Jul. 04, 2021 | |
Product Warranties Disclosures [Abstract] | |
Warranty Reserves | Warranty Reserves The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets. A summary of warranty reserve activity is as follows: Three Months Ended July 4, July 5, (In thousands) Balance at beginning of period $ 12,073 $ 8,812 Provision charged to income 3,691 2,712 Payments (6,182) (3,266) Adjustments to previously provided warranties, net 2,455 1,052 Foreign currency translation and acquisitions (190) (269) Balance at end of period $ 11,847 $ 9,041 |
Employee Benefit Plans
Employee Benefit Plans | 6 Months Ended |
Jul. 04, 2021 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | Employee Postretirement Benefit Plans The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans: Defined Benefit Postretirement Three Months Ended July 4, July 5, July 4, July 5, (In thousands) Service and administrative costs $ 1,338 $ 1,688 $ 15 $ 18 Interest cost 2,376 3,138 17 23 Expected return on plan assets (6,121) (5,371) (397) (347) Net periodic pension credit $ (2,407) $ (545) $ (365) $ (306) Defined Benefit Postretirement Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Service and administrative costs $ 2,672 $ 3,595 $ 29 $ 36 Interest cost 4,753 6,282 34 47 Expected return on plan assets (12,248) (10,755) (794) (694) Net periodic benefit credit $ (4,823) $ (878) $ (731) $ (611) During the six months ended July 4, 2021 and July 5, 2020, the Company contributed $3.7 million and $3.4 million, respectively, in the aggregate, to pension plans outside of the United States. During the six months ended July 4, 2021, the Company contributed $20.0 million to its defined benefit pension plan in the United States for the plan year 2019. The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2020 Form 10-K. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions. Service costs for plans in active accrual are included in operating expenses. |
Derivatives And Hedging Activit
Derivatives And Hedging Activities | 6 Months Ended |
Jul. 04, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives and Hedging Activities | Derivatives and Hedging Activities The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 70% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows. Principal hedged currencies include the Australian Dollar, British Pound, Euro, Indian Rupee, Singapore Dollar and Swedish Krona. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $444.7 million, $808.0 million and $358.7 million at July 4, 2021, January 3, 2021 and July 5, 2020, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the six months ended July 4, 2021 and July 5, 2020. In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements included combined U.S. Dollar notional amounts of $309.4 million as of July 4, 2021, combined Euro notional amounts of €33.4 million and combined U.S. Dollar notional amounts of $499.0 million as of January 3, 2021, and combined Euro notional amounts of €104.8 million and combined U.S. Dollar notional amounts of $267.0 million as of July 5, 2020. The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the three and six months ended July 4, 2021 and July 5, 2020. The Company paid $5.9 million and received $5.0 million during the six months ended July 4, 2021 and July 5, 2020, respectively, from the settlement of these hedges. During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its net investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of accumulated other comprehensive income ("AOCI"), which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of July 4, 2021, the total notional amount of the 2026 Notes that was designated to hedge net investments in foreign subsidiaries was €299.7 million. The unrealized foreign exchange losses (gains) recorded in AOCI related to the net investment hedge were $2.5 million and $(19.1) million for the three and six months ended July 4, 2021, respectively, and $22.3 million and $1.3 million for the three and six months ended July 5, 2020, respectively. During fiscal year 2019, the Company entered into a cross-currency swap designated as a net investment hedge to hedge the Euro currency exposure of the Company’s net investment in certain foreign subsidiaries. This agreement is a contract to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. Changes in the fair value of this swap are recorded in equity as a component of AOCI in the same manner as foreign currency translation adjustments. In assessing the effectiveness of this hedge, the Company uses a method based on changes in spot rates to measure the impact of the foreign currency exchange rate fluctuations on both its foreign subsidiary net investment and the related swap. Under this method, changes in the fair value of the hedging instrument other than those due to changes in the spot rate are initially recorded in AOCI as a translation adjustment, and then are amortized into other (income) expense, net in the condensed consolidated statement of operations using a systematic and rational method over the instrument’s term. Changes in the fair value associated with the effective portion (i.e. those changes due to the spot rate) are recorded in AOCI as a translation adjustment and are released and recognized in earnings only upon the sale or liquidation of the hedged net investment. The cross-currency swap has an initial notional value of €197.4 million, or $220.0 million, and matures on November 15, 2021. Interest on the cross-currency swap is payable semi-annually, in Euro, on May 15th and November 15th of each year based on the Euro notional value and a fixed rate of 2.47%. The Company receives interest in U.S. dollars on May 15th and November 15th of each year based on the U.S. dollar equivalent of the Euro notional value and a fixed rate of 5.00%. At July 4, 2021, the fair value of the cross-currency swap was a $13.0 million loss, which was recorded in AOCI. During fiscal year 2020, the Company entered into a forward foreign exchange contracts, designated as cash flow hedges, to hedge the 2021 Notes. The effective portion of the gain or loss of the cash flow hedges were reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affected earnings. During the second quarter of fiscal year 2021, the Company redeemed all of its outstanding 2021 Notes and settled the forward foreign exchange contracts that were designated as cash flow hedges. The unrealized foreign exchange (gains) losses recorded in earnings related to the cash flow hedges were $(4.1) million and $9.5 million for the three and six months ended July 4, 2021, respectively, and $(3.8) million for each of the three and six months ended July 5, 2020. During fiscal year 2021, the Company entered into forward foreign exchange contracts, designated as a cash flow hedge, to hedge a portion of the 2026 Notes. The effective portion of the gain or loss of the cash flow hedge will be reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affects earnings. As of July 4, 2021, the total notional amount of the forward foreign exchange contracts that was designated as cash flow hedges was €197.4 million. The unrealized foreign exchange gains recorded in earnings related to the cash flow hedge were $1.7 million and $0.8 million for the three and six months ended July 4, 2021. The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jul. 04, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of July 4, 2021. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the six months ended July 4, 2021. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of July 4, 2021 and January 3, 2021 classified in one of the three classifications described above: Fair Value Measurements at July 4, 2021 Using: Total Carrying Value at July 4, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 50,100 $ 50,100 $ — $ — Foreign exchange derivative assets 2,663 — 2,663 — Foreign exchange derivative liabilities (13,670) — (13,670) — Contingent consideration (3,334) — — (3,334) Fair Value Measurements at January 3, 2021 Using: Total Carrying Value at January 3, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,154 $ 2,154 $ — $ — Foreign exchange derivative assets 31,248 — 31,248 — Foreign exchange derivative liabilities (21,413) — (21,413) — Contingent consideration (2,953) — — (2,953) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both July 4, 2021 and January 3, 2021, none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets as compared to initial projections, with the impact of such adjustments being recorded in the Company's consolidated statements of operations. As of July 4, 2021, the Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $7.2 million. The expected maximum earnout period for the acquisitions with open contingency periods does not exceed 1.5 years from July 4, 2021, and the remaining weighted average expected earnout period at July 4, 2021 was 0.8 years. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Balance at beginning of period $ (3,124) $ (22,777) $ (2,953) $ (35,481) Amounts paid and foreign currency translation 27 9,930 96 10,309 Change in fair value (included within selling, general and administrative expenses) (237) (879) (477) 11,446 Balance at end of period $ (3,334) $ (13,726) $ (3,334) $ (13,726) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. The Company's outstanding senior unsecured notes had a fair value of $2,411.6 million and a carrying value of $2,219.7 million as of July 4, 2021. The Company's outstanding senior unsecured notes had a fair value of $1,984.3 million and a carrying value of $1,811.5 million as of January 3, 2021. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements. The Company’s other debt facilities, including the Company's senior revolving credit facility, had an aggregate carrying value of $133.5 million and $179.1 million as of July 4, 2021 and January 3, 2021, respectively. As of July 4, 2021, these included bank loans in the aggregate amount of $10.7 million bearing fixed interest rates between 1.1% and 8.9% and a bank loan in the amount of $23,000 bearing a variable interest rate based on the Euribor rate plus a margin of 1.5%. The Company had no change in credit standing during the first six months of fiscal year 2021. Consequently, the carrying value approximates fair value and were classified as Level 2. As of July 4, 2021, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks. |
Contingencies
Contingencies | 6 Months Ended |
Jul. 04, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies | Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.1 million and $12.9 million as of July 4, 2021 and January 3, 2021, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at July 4, 2021 would not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. |
Basis of Presentation (Policies
Basis of Presentation (Policies) | 6 Months Ended |
Jul. 04, 2021 | |
Accounting Policies [Abstract] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the "FASB") and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations. In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 eliminates certain exceptions and adds guidance to reduce complexity in accounting for income taxes. Specifically, this guidance: (1) removes the intraperiod tax allocation exception to the incremental approach; (2) removes the ownership changes in investments exception in determining when a deferred tax liability is recognized after an investor in a foreign entity transitions to or from the equity method of accounting and applies this provision on a modified retrospective basis through a cumulative-effect adjustment to retained earnings at the beginning of the period of adoption; and (3) removes the exception to using the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. ASU 2019-12 also simplifies accounting principles by making other changes, including requiring an entity to: (1) evaluate whether a step-up in tax basis of goodwill relates to a business combination or a separate transaction; (2) make a policy election to not allocate consolidated income taxes when a member of a consolidated tax return is not subject to income tax and to apply this provision retrospectively to all periods presented; and (3) recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and apply this provision either retrospectively for all periods presented or on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The provisions of this guidance (except as specifically mentioned above) are to be applied prospectively upon their effective date. ASU 2019-12 is effective for annual reporting periods beginning after December 15, 2020, and interim p eriods within those years. In accordance with ASU 2019-12, the Company adopted the guidance beginning on January 4, 2021. The adoption did not have a material impact on the Company's consolidated financial position, results of operations and cash flows. |
Revenue (Tables)
Revenue (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Disaggregation of Revenue [Line Items] | |
Disaggregation of Revenue [Table Text Block] | In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue. Reportable Segments Three Months Ended July 4, 2021 July 5, 2020 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 206,938 $ 368,365 $ 575,303 $ 160,382 $ 156,609 $ 316,991 Europe 145,576 200,777 346,353 103,497 149,867 253,364 Asia 160,315 146,500 306,815 127,123 114,240 241,363 $ 512,829 $ 715,642 $ 1,228,471 $ 391,002 $ 420,716 $ 811,718 Primary end-markets Diagnostics $ — $ 715,642 $ 715,642 $ — $ 420,716 $ 420,716 Life sciences 308,681 — 308,681 237,120 — 237,120 Applied markets 204,148 — 204,148 153,882 — 153,882 $ 512,829 $ 715,642 $ 1,228,471 $ 391,002 $ 420,716 $ 811,718 Timing of revenue recognition Products and services transferred at a point in time $ 378,310 $ 506,603 $ 884,913 $ 265,903 $ 398,646 $ 664,549 Services transferred over time 134,519 209,039 343,558 125,099 22,070 147,169 $ 512,829 $ 715,642 $ 1,228,471 $ 391,002 $ 420,716 $ 811,718 Reportable Segments Six Months Ended July 4, 2021 July 5, 2020 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 382,053 $ 769,292 $ 1,151,345 $ 329,498 $ 261,766 $ 591,264 Europe 281,034 512,520 793,554 222,154 231,466 453,620 Asia 304,351 286,910 591,261 237,745 181,485 419,230 $ 967,438 $ 1,568,722 $ 2,536,160 $ 789,397 $ 674,717 $ 1,464,114 Primary end-markets Diagnostics $ — $ 1,568,722 $ 1,568,722 $ — $ 674,717 $ 674,717 Life sciences 585,882 — 585,882 482,853 — 482,853 Applied markets 381,556 — 381,556 306,544 — 306,544 $ 967,438 $ 1,568,722 $ 2,536,160 $ 789,397 $ 674,717 $ 1,464,114 Timing of revenue recognition Products and services transferred at a point in time $ 704,972 $ 1,121,709 $ 1,826,681 $ 533,810 $ 630,299 $ 1,164,109 Services transferred over time 262,466 447,013 709,479 255,587 44,418 300,005 $ 967,438 $ 1,568,722 $ 2,536,160 $ 789,397 $ 674,717 $ 1,464,114 |
Business Combinations (Tables)
Business Combinations (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Business Acquisition [Line Items] | |
Schedule of Business Acquisitions, by Acquisition1 [Table Text Block] | The total purchase price for the acquisitions in fiscal year 2020 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: Preliminary (In thousands) Fair value of business combination: Cash payments $ 437,661 Other liability 1,660 Working capital and other adjustments (384) Less: cash acquired (26,840) Total $ 412,097 Identifiable assets acquired and liabilities assumed: Current assets $ 35,532 Property, plant and equipment 20,302 Other assets 18,114 Identifiable intangible assets: Core technology 65,730 Trade names 5,580 Customer relationships 108,523 Goodwill 221,960 Deferred taxes (27,142) Deferred revenue (2,031) Liabilities assumed (45,171) Total $ 412,097 |
Restructuring and Lease Charg_2
Restructuring and Lease Charges, Net (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Restructuring Cost and Reserve [Line Items] | |
Schedule of Restructuring Plan Activity [Table Text Block] | The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2021 and 2020 in continuing operations: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q2 2021 Plan 25 $ 968 $ 564 $ — $ — $ 1,532 Q1 FY2022 — Q1 2021 Plan 77 3,941 1,615 — — 5,556 Q4 FY2021 — Q3 2020 Plan 23 2,080 901 — — 2,981 Q2 FY2021 — Q1 2020 Plan 32 2,312 1,134 92 682 4,220 Q4 FY2020 Q1 FY2022 |
Interest and Other Expense (I_2
Interest and Other Expense (Income), Net (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Other Income and Expenses [Abstract] | |
Interest and Other Expense (Income), Net | Interest and other expense, net, consisted of the following: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Interest income $ (367) $ (192) $ (778) $ (457) Interest expense 16,750 11,586 30,876 25,251 Change in fair value of financial securities (8,633) — (27,931) — Other income, net (1,319) (582) (8,442) (3,989) Total interest and other (income) expense, net $ 6,431 $ 10,812 $ (6,275) $ 20,805 |
Inventories, Net (Tables)
Inventories, Net (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of Net Inventories | Inventories consisted of the following: July 4, January 3, (In thousands) Raw materials $ 199,770 $ 205,022 Work in progress 40,646 35,160 Finished goods 273,013 274,385 Total inventories $ 513,429 $ 514,567 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | The Company’s debt consisted of the following: July 4, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ 125,000 $ — $ (2,264) $ 122,736 1.875% Senior Unsecured Notes due in 2026 ("2026 Notes") 592,300 (2,904) (2,531) 586,865 3.3% Senior Unsecured Notes due in 2029 ("2029 Notes") 850,000 (2,368) (6,556) 841,076 2.55% Senior Unsecured Notes due in 2031 400,000 (136) (3,563) 396,301 3.625% Senior Unsecured Notes due in 2051 400,000 (4) (4,545) 395,451 Other Debt Facilities, non-current 6,094 — — 6,094 Total Long-Term Debt $ 2,373,394 $ (5,412) $ (19,459) $ 2,348,523 Current Portion of Long-term Debt: Other Debt Facilities, current 4,669 — — 4,669 Total $ 2,378,063 $ (5,412) $ (19,459) $ 2,353,192 January 3, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ 158,595 $ — $ (2,621) $ 155,974 2026 Notes 610,750 (3,253) (2,782) 604,715 2029 Notes 850,000 (2,496) (6,908) 840,596 Other Debt Facilities, non-current 8,416 — — 8,416 Total Long-Term Debt $ 1,627,761 $ (5,749) $ (12,311) $ 1,609,701 Current Portion of Long-term Debt: 0.6% Senior Unsecured Notes due in 2021 ("2021 Notes") 366,450 (16) (229) 366,205 Other Debt Facilities, current 14,743 — — 14,743 Total $ 2,008,954 $ (5,765) $ (12,540) $ 1,990,649 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations | The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Number of common shares—basic 111,973 111,329 112,000 111,225 Effect of dilutive securities: Stock options 344 470 352 475 Restricted stock awards 100 70 104 56 Number of common shares—diluted 112,417 111,869 112,456 111,756 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 224 390 193 440 |
Industry Segment Information (T
Industry Segment Information (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Segment Reporting [Abstract] | |
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations | Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Discovery & Analytical Solutions Product revenue $ 318,085 $ 225,617 $ 585,340 $ 440,973 Service revenue 194,744 165,385 382,098 348,424 Total revenue 512,829 391,002 967,438 789,397 Operating income from continuing operations 64,155 39,430 107,102 67,943 Diagnostics Product revenue 449,674 375,889 993,971 586,062 Service revenue 265,968 44,827 574,751 88,655 Total revenue 715,642 420,716 1,568,722 674,717 Operating income from continuing operations 286,280 160,300 727,747 189,891 Corporate Operating loss from continuing operations (17,947) (24,091) (34,585) (37,513) Continuing Operations Product revenue 767,759 601,506 1,579,311 1,027,035 Service revenue 460,712 210,212 956,849 437,079 Total revenue 1,228,471 811,718 2,536,160 1,464,114 Operating income from continuing operations 332,488 175,639 800,264 220,321 Interest and other expense (income), net (see Note 5) 6,431 10,812 (6,275) 20,805 Income from continuing operations before income taxes $ 326,057 $ 164,827 $ 806,539 $ 199,516 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Stockholders' Equity Note [Abstract] | |
Components of Accumulated Other Comprehensive Loss | The components of accumulated other comprehensive loss consisted of the following: July 4, January 3, (In thousands) Foreign currency translation adjustments, net of income taxes $ (91,518) $ (30,937) Unrecognized prior service costs, net of income taxes (747) (747) Unrealized net losses on securities, net of income taxes (172) (277) Accumulated other comprehensive loss $ (92,437) $ (31,961) |
Stock Plans (Tables)
Stock Plans (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Summary of Total Compensation Recognized Related to Outstanding Equity Awards | The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock option grants, restricted stock awards, performance restricted stock units, performance units and stock awards, included in the Company’s condensed consolidated statements of operations for the three and six months ended July 4, 2021 and July 5, 2020: Three Months Ended July 4, July 5, (In thousands) Cost of revenue $ 692 $ 253 Research and development expenses 366 316 Selling, general and administrative expenses 6,146 9,034 Total stock-based compensation expense $ 7,204 $ 9,603 The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $4.1 million and $2.2 million for the three and six months ended July 4, 2021 and July 5, 2020, respectively. Stock-based compensation costs capitalized as part of inventory were $0.5 million and $0.3 million as of July 4, 2021 and July 5, 2020, respectively. |
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model | The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows: Three and Six Months Ended July 4, July 5, Risk-free interest rate 0.6 % 0.9 % Expected dividend yield 0.2 % 0.3 % Expected term 5 years 5 years Expected stock volatility 27.3 % 23.8 % |
Summary of Stock Option Activity | The following table summarizes stock option activity for the six months ended July 4, 2021: Number Weighted- Weighted-Average Total (In thousands) (In years) (In millions) Outstanding at January 3, 2021 961 $ 74.40 Granted 162 134.53 Exercised (96) 53.98 Forfeited (7) 88.54 Outstanding at July 4, 2021 1,020 $ 85.78 4.3 $ 46.2 Exercisable at July 4, 2021 640 $ 72.63 3.2 $ 36.7 |
Summary of Restricted Stock Award Activity | The following table summarizes restricted stock award activity for the six months ended July 4, 2021: Number of Weighted- (In thousands) Nonvested at January 3, 2021 296 $ 85.67 Granted 102 129.27 Vested (102) 83.16 Forfeited (5) 86.90 Nonvested at July 4, 2021 291 $ 101.83 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets, Net (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Changes in the Carrying Amount of Goodwill | The changes in the carrying amount of goodwill for the six months ended July 4, 2021 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at January 3, 2021 $ 1,755,887 $ 1,691,227 $ 3,447,114 Foreign currency translation (19,151) (17,806) (36,957) Acquisitions, earn-outs and other 155,199 278,714 433,913 Balance at July 4, 2021 $ 1,891,935 $ 1,952,135 $ 3,844,070 |
Identifiable Intangible Asset Balances | Identifiable intangible asset balances by category were as follows: July 4, January 3, (In thousands) Patents $ 31,042 $ 30,855 Less: Accumulated amortization (28,590) (28,440) Net patents 2,452 2,415 Trade names and trademarks 122,959 98,661 Less: Accumulated amortization (54,468) (48,806) Net trade names and trademarks 68,491 49,855 Licenses 59,015 58,700 Less: Accumulated amortization (53,391) (52,452) Net licenses 5,624 6,248 Core technology 980,388 789,799 Less: Accumulated amortization (435,709) (398,992) Net core technology 544,679 390,807 Customer relationships 1,441,419 1,357,660 Less: Accumulated amortization (582,624) (522,820) Net customer relationships 858,795 834,840 In-process research and development 10,909 10,944 Net amortizable intangible assets 1,490,950 1,295,109 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 1,561,534 $ 1,365,693 |
Warranty Reserves (Tables)
Warranty Reserves (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Product Warranties Disclosures [Abstract] | |
Warranty Reserve Activity | A summary of warranty reserve activity is as follows: Three Months Ended July 4, July 5, (In thousands) Balance at beginning of period $ 12,073 $ 8,812 Provision charged to income 3,691 2,712 Payments (6,182) (3,266) Adjustments to previously provided warranties, net 2,455 1,052 Foreign currency translation and acquisitions (190) (269) Balance at end of period $ 11,847 $ 9,041 |
Employee Benefit Plans (Tables)
Employee Benefit Plans (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Retirement Benefits [Abstract] | |
Components of Net Periodic Benefit Cost (Credit) | The following table summarizes the components of net periodic pension credit for the Company’s various defined benefit employee pension and postretirement plans: Defined Benefit Postretirement Three Months Ended July 4, July 5, July 4, July 5, (In thousands) Service and administrative costs $ 1,338 $ 1,688 $ 15 $ 18 Interest cost 2,376 3,138 17 23 Expected return on plan assets (6,121) (5,371) (397) (347) Net periodic pension credit $ (2,407) $ (545) $ (365) $ (306) Defined Benefit Postretirement Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Service and administrative costs $ 2,672 $ 3,595 $ 29 $ 36 Interest cost 4,753 6,282 34 47 Expected return on plan assets (12,248) (10,755) (794) (694) Net periodic benefit credit $ (4,823) $ (878) $ (731) $ (611) |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jul. 04, 2021 | |
Fair Value Disclosures [Abstract] | |
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis | The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of July 4, 2021 and January 3, 2021 classified in one of the three classifications described above: Fair Value Measurements at July 4, 2021 Using: Total Carrying Value at July 4, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 50,100 $ 50,100 $ — $ — Foreign exchange derivative assets 2,663 — 2,663 — Foreign exchange derivative liabilities (13,670) — (13,670) — Contingent consideration (3,334) — — (3,334) Fair Value Measurements at January 3, 2021 Using: Total Carrying Value at January 3, 2021 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 2,154 $ 2,154 $ — $ — Foreign exchange derivative assets 31,248 — 31,248 — Foreign exchange derivative liabilities (21,413) — (21,413) — Contingent consideration (2,953) — — (2,953) |
Reconciliation of Beginning and Ending Level 3 Net Liabilities | A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended Six Months Ended July 4, July 5, July 4, July 5, (In thousands) Balance at beginning of period $ (3,124) $ (22,777) $ (2,953) $ (35,481) Amounts paid and foreign currency translation 27 9,930 96 10,309 Change in fair value (included within selling, general and administrative expenses) (237) (879) (477) 11,446 Balance at end of period $ (3,334) $ (13,726) $ (3,334) $ (13,726) |
Basis of Presentation (Basis of
Basis of Presentation (Basis of Presentation) (Details) - USD ($) $ in Thousands | 6 Months Ended | |||
Jul. 04, 2021 | Jul. 05, 2020 | Jan. 03, 2021 | Apr. 05, 2020 | |
Basis of Presentation [Line Items] | ||||
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $ (10,659) | $ (4,658) | ||
Operating Lease, Right-of-Use Asset | $ 208,494 | $ 207,236 | ||
Accounting Standards Update 2016-02 [Member] | ||||
Basis of Presentation [Line Items] | ||||
Cumulative Effect of New Accounting Pronouncement in Period of Adoption | $ (1,328) |
Revenue (Details)
Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | Jan. 03, 2021 | |
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 1,228,471 | $ 811,718 | $ 2,536,160 | $ 1,464,114 | |
Contract with Customer, Asset and Liability [Abstract] | |||||
Contract with Customer, Asset, Net, Current | 51,900 | 51,900 | $ 59,500 | ||
Contract with Customer, Liability, Current | 230,700 | 230,700 | $ 238,100 | ||
Contract with Customer, Liability, Revenue Recognized | (57,100) | ||||
Unbilled Receivables Transferred To Accounts Receivables | (46,200) | ||||
Contract with Customer, Liability, Increase (Decrease) | 49,600 | ||||
Contract with Customer, Asset, Increase (Decrease) | 38,600 | ||||
Transferred at Point in Time [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 884,913 | 664,549 | 1,826,681 | 1,164,109 | |
Transferred over Time [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 343,558 | 147,169 | 709,479 | 300,005 | |
Americas [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 575,303 | 316,991 | 1,151,345 | 591,264 | |
Europe [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 346,353 | 253,364 | 793,554 | 453,620 | |
Asia [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 306,815 | 241,363 | 591,261 | 419,230 | |
Discovery & Analytical Solutions [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 512,829 | 391,002 | 967,438 | 789,397 | |
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 378,310 | 265,903 | 704,972 | 533,810 | |
Discovery & Analytical Solutions [Member] | Transferred over Time [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 134,519 | 125,099 | 262,466 | 255,587 | |
Discovery & Analytical Solutions [Member] | Americas [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 206,938 | 160,382 | 382,053 | 329,498 | |
Discovery & Analytical Solutions [Member] | Europe [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 145,576 | 103,497 | 281,034 | 222,154 | |
Discovery & Analytical Solutions [Member] | Asia [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 160,315 | 127,123 | 304,351 | 237,745 | |
Diagnostics [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 | |
Diagnostics [Member] | Customer Concentration Risk [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 192,500 | 398,000 | |||
Diagnostics [Member] | Transferred at Point in Time [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 506,603 | 398,646 | 1,121,709 | 630,299 | |
Diagnostics [Member] | Transferred over Time [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 209,039 | 22,070 | 447,013 | 44,418 | |
Diagnostics [Member] | Americas [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 368,365 | 156,609 | 769,292 | 261,766 | |
Diagnostics [Member] | Europe [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 200,777 | 149,867 | 512,520 | 231,466 | |
Diagnostics [Member] | Asia [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 146,500 | 114,240 | 286,910 | 181,485 | |
Life Sciences [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 308,681 | 237,120 | 585,882 | 482,853 | |
Life Sciences [Member] | Discovery & Analytical Solutions [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 308,681 | 237,120 | 585,882 | 482,853 | |
Life Sciences [Member] | Diagnostics [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 | |
Diagnostics [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 | |
Diagnostics [Member] | Discovery & Analytical Solutions [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0 | |
Diagnostics [Member] | Diagnostics [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 | |
Applied Markets [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 204,148 | 153,882 | 381,556 | 306,544 | |
Applied Markets [Member] | Discovery & Analytical Solutions [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | 204,148 | 153,882 | 381,556 | 306,544 | |
Applied Markets [Member] | Diagnostics [Member] | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 | $ 0 | $ 0 | $ 0 |
Changes in Accounting Policies
Changes in Accounting Policies (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||||||
Jul. 04, 2021 | Apr. 04, 2021 | Jul. 05, 2020 | Apr. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | Jan. 03, 2021 | Dec. 29, 2019 | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||||||||
Cost of Goods and Services Sold | $ (543,277) | $ (364,374) | $ (1,065,820) | $ (708,747) | ||||
Selling, general and administrative expenses | 281,819 | 221,026 | 533,229 | 429,595 | ||||
Research and development expenses | 65,824 | 49,521 | 126,040 | 98,435 | ||||
Restructuring and other costs, net | 5,063 | 1,158 | 10,807 | 7,016 | ||||
Operating income (loss) from continuing operations | 332,488 | 175,639 | 800,264 | 220,321 | ||||
Nonoperating Income (Expense) | 6,431 | 10,812 | (6,275) | 20,805 | ||||
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | 326,057 | 164,827 | 806,539 | 199,516 | ||||
Provision for income taxes | 80,089 | 27,614 | 181,228 | 28,588 | ||||
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | 245,968 | 137,213 | 625,311 | 170,928 | ||||
Loss on disposition of discontinued operations before income taxes | 0 | 0 | 0 | 0 | ||||
Cash and cash equivalents | 572,810 | 218,536 | 572,810 | 218,536 | $ 402,036 | |||
Accounts receivable, net | (992,602) | (992,602) | (1,155,109) | |||||
Inventories | 513,429 | 513,429 | 514,567 | |||||
Other current assets | (181,151) | (181,151) | (167,208) | |||||
Property, Plant and Equipment, Net | 379,065 | 379,065 | 368,304 | |||||
Intangible assets, net | 1,561,534 | 1,561,534 | 1,365,693 | |||||
Goodwill | 3,844,070 | 3,844,070 | 3,447,114 | |||||
Other assets, net | 486,306 | 486,306 | 333,048 | |||||
Assets | (8,739,461) | (8,739,461) | (7,960,315) | |||||
Current portion of long-term debt | 4,669 | 4,669 | 380,948 | |||||
Accounts payable | 324,711 | 324,711 | 327,325 | |||||
Accrued expenses and other current liabilities | 793,443 | 793,443 | 943,916 | |||||
Long-term debt | 2,348,523 | 2,348,523 | 1,609,701 | |||||
Long-term liabilities | 838,974 | 838,974 | 774,531 | |||||
Liabilities | 4,499,654 | 4,499,654 | 4,224,823 | |||||
Preferred Stock, Value, Issued | 0 | 0 | 0 | |||||
Common Stock, Value, Issued | 112,025 | 112,025 | 112,090 | |||||
Capital in excess of par value | 103,394 | 103,394 | 148,101 | |||||
Retained earnings | 4,116,825 | 4,116,825 | 3,507,262 | |||||
Accumulated other comprehensive loss | (92,437) | (92,437) | (31,961) | |||||
Stockholders' Equity Attributable to Parent | 4,239,807 | $ 4,002,305 | 2,967,463 | $ 2,759,746 | 4,239,807 | 2,967,463 | 3,735,492 | $ 2,813,824 |
Liabilities and Equity | (8,739,461) | (8,739,461) | $ (7,960,315) | |||||
Discontinued Operation, Tax Effect of Discontinued Operation | 38 | 51 | 76 | 101 | ||||
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | (38) | (51) | (76) | (101) | ||||
Net income | $ 245,930 | $ 379,305 | $ 137,162 | $ 33,665 | $ 625,235 | $ 170,827 |
Business Combinations (Narrativ
Business Combinations (Narrative) (Details) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Jul. 04, 2021USD ($)employees | Jul. 05, 2020USD ($) | Jul. 04, 2021USD ($)employees | Jul. 05, 2020USD ($) | Oct. 03, 2021USD ($)employees | Jan. 03, 2021USD ($)employees | Apr. 04, 2021USD ($) | Apr. 05, 2020USD ($) | Dec. 29, 2019USD ($) | |
Business Acquisition [Line Items] | |||||||||
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions | 1 year | ||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 3,334,000 | $ 13,726,000 | $ 3,334,000 | $ 13,726,000 | $ 2,953,000 | $ 3,124,000 | $ 22,777,000 | $ 35,481,000 | |
Total transaction costs | (10,600,000) | (5,200,000) | (15,100,000) | (7,100,000) | |||||
Goodwill | 3,844,070,000 | 3,844,070,000 | 3,447,114,000 | ||||||
Business Combination, Contingent Consideration, Liability, Current | 3,200,000 | 3,200,000 | 2,900,000 | ||||||
Business Combination, Contingent Consideration, Liability, Noncurrent | 100,000 | 100,000 | 100,000 | ||||||
Foreign Currency Transaction Gain (Loss), before Tax | 800,000 | 6,400,000 | (600,000) | (3,500,000) | |||||
Interest Expense | 16,750,000 | 11,586,000 | 30,876,000 | 25,251,000 | |||||
Business Combination, Contingent Consideration, Liability | 3,300,000 | 3,300,000 | 3,000,000 | ||||||
Fiscal Year 2021 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Consideration Transferred | 703,180,000 | ||||||||
Cash Acquired | 157,278,000 | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 35,265,000 | 35,265,000 | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 13,293,000 | 13,293,000 | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 15,187,000 | 15,187,000 | |||||||
Cash paid to the shareholders | 859,548,000 | ||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 910,000 | ||||||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 11 years 10 months 24 days | ||||||||
Goodwill | 428,923,000 | $ 428,923,000 | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | 44,417,000 | 44,417,000 | |||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 703,180,000 | $ 703,180,000 | |||||||
Oxford Immunotec [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Entity Number of Employees | employees | 275 | 275 | |||||||
Foreign Currency Transaction Gain (Loss), before Tax | $ (5,400,000) | ||||||||
Interest Expense | $ 200,000 | ||||||||
Nexcelom Bioscience [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Entity Number of Employees | employees | 130 | 130 | |||||||
Fiscal Year 2020 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments | 384,000 | ||||||||
Business Combination, Consideration Transferred | 412,097,000 | ||||||||
Cash Acquired | (26,840,000) | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 35,532,000 | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 20,302,000 | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 18,114,000 | ||||||||
Cash paid to the shareholders | 437,661,000 | ||||||||
Business Combination, Consideration Transferred, Liabilities Incurred | $ 1,660,000 | ||||||||
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | 11 years | ||||||||
Goodwill | $ 221,960,000 | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | 45,171,000 | ||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 412,097,000 | ||||||||
Horizon Discovery Group plc [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Entity Number of Employees | employees | 400 | ||||||||
Shandong Meizheng [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Compensation Expense, Excluding Cost of Good and Service Sold | $ (6,300,000) | $ (5,600,000) | $ (11,700,000) | $ (6,700,000) | |||||
Diagnostics [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Goodwill | 1,952,135,000 | 1,952,135,000 | $ 1,691,227,000 | ||||||
Discovery & Analytical Solutions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Goodwill | 1,891,935,000 | 1,891,935,000 | 1,755,887,000 | ||||||
Core Technology [Member] | Fiscal Year 2021 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 193,260,000 | 193,260,000 | |||||||
Core Technology [Member] | Fiscal Year 2020 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 65,730,000 | ||||||||
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 104,270,000 | 104,270,000 | |||||||
Customer Relationships [Member] | Fiscal Year 2020 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 108,523,000 | ||||||||
Trade Names [Member] | Fiscal Year 2021 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 26,070,000 | 26,070,000 | |||||||
Trade Names [Member] | Fiscal Year 2020 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 5,580,000 | ||||||||
Subsequent Event [Member] | SIRION Biotech [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Entity Number of Employees | employees | 50 | ||||||||
Subsequent Event [Member] | BioLegend [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Entity Number of Employees | employees | 700 | ||||||||
Euro Member Countries, Euro | Subsequent Event [Member] | SIRION Biotech [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 80,000,000 | ||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 72,000,000 | ||||||||
United States of America, Dollars | Fiscal Year 2021 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 860,500,000 | ||||||||
United States of America, Dollars | Oxford Immunotec [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 590,900,000 | ||||||||
United States of America, Dollars | Nexcelom Bioscience [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 267,100,000 | ||||||||
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 2,500,000 | ||||||||
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 438,900,000 | ||||||||
United States of America, Dollars | Horizon Discovery Group plc [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 399,800,000 | ||||||||
United States of America, Dollars | Fiscal Year 2020 Other Acquisitions | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 39,100,000 | ||||||||
United States of America, Dollars | Subsequent Event [Member] | SIRION Biotech [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 94,800,000 | ||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 85,300,000 | ||||||||
United States of America, Dollars | Subsequent Event [Member] | Immunodiagnostic Systems [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 155,000,000 | ||||||||
United States of America, Dollars | Subsequent Event [Member] | BioLegend [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 5,250,000,000 | ||||||||
United Kingdom, Pounds | Horizon Discovery Group plc [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 296,000,000 | ||||||||
United Kingdom, Pounds | Subsequent Event [Member] | Immunodiagnostic Systems [Member] | |||||||||
Business Acquisition [Line Items] | |||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | $ 110,000,000 |
Business Combinations (Fair Val
Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jul. 04, 2021 | Jan. 03, 2021 | |
Business Acquisition [Line Items] | ||
Goodwill | $ 3,844,070,000 | $ 3,447,114,000 |
Fiscal Year 2021 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 859,548,000 | |
Business Combination, Consideration Transferred, Liabilities Incurred | 910,000 | |
Cash Acquired | 157,278,000 | |
Business Combination, Consideration Transferred | 703,180,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 35,265,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 13,293,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 15,187,000 | |
Goodwill | 428,923,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (68,821,000) | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (44,417,000) | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 703,180,000 | |
Fiscal Year 2020 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 437,661,000 | |
Business Combination, Consideration Transferred, Liabilities Incurred | 1,660,000 | |
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments | 384,000 | |
Cash Acquired | (26,840,000) | |
Business Combination, Consideration Transferred | 412,097,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 35,532,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | 20,302,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 18,114,000 | |
Goodwill | 221,960,000 | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total | (27,142,000) | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue | (2,031,000) | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | (45,171,000) | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | 412,097,000 | |
Core Technology [Member] | Fiscal Year 2021 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 193,260,000 | |
Core Technology [Member] | Fiscal Year 2020 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 65,730,000 | |
Trade Names [Member] | Fiscal Year 2021 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 26,070,000 | |
Trade Names [Member] | Fiscal Year 2020 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 5,580,000 | |
Patents [Member] | Fiscal Year 2021 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 150,000 | |
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 104,270,000 | |
Customer Relationships [Member] | Fiscal Year 2020 Acquisitions [Member] | ||
Business Acquisition [Line Items] | ||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | 108,523,000 | |
Diagnostics [Member] | ||
Business Acquisition [Line Items] | ||
Goodwill | 1,952,135,000 | 1,691,227,000 |
Discovery & Analytical Solutions [Member] | ||
Business Acquisition [Line Items] | ||
Goodwill | $ 1,891,935,000 | $ 1,755,887,000 |
Discontinued Operations (Narrat
Discontinued Operations (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | $ (38) | $ (51) | $ (76) | $ (101) |
Pre-tax gain (loss) on disposal of business unit | 0 | 0 | 0 | 0 |
Discontinued Operation, Tax Effect of Discontinued Operation | $ 38 | $ 51 | $ 76 | $ 101 |
Restructuring and Lease Charg_3
Restructuring and Lease Charges, Net (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended |
Jul. 04, 2021 | Jul. 04, 2021 | |
Diagnostics [Member] | Facility Relocation [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and contract termination charges, net | $ 200 | |
Diagnostics [Member] | Contract Termination [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and contract termination charges, net | 700 | |
Discovery & Analytical Solutions [Member] | Facility Relocation [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and contract termination charges, net | $ 2,300 | 2,500 |
Discovery & Analytical Solutions [Member] | Contract Termination [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and contract termination charges, net | $ 400 |
Restructuring and Lease Charg_4
Restructuring and Lease Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jul. 04, 2021USD ($)employees | Apr. 04, 2021USD ($)employees | Oct. 04, 2020USD ($)employees | Apr. 05, 2020USD ($)employees | Jul. 04, 2021USD ($) | |
Q2 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 25 | ||||
Restructuring and contract termination charges, net | $ 1,532 | ||||
Q1 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 77 | ||||
Restructuring and contract termination charges, net | $ 5,556 | ||||
Q3 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 23 | ||||
Restructuring and contract termination charges, net | $ 2,981 | ||||
Q1 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and Related Cost, Number of Positions Eliminated | employees | 32 | ||||
Restructuring and contract termination charges, net | $ 4,220 | ||||
Diagnostics [Member] | Employee Severance [Member] | Q2 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 564 | ||||
Diagnostics [Member] | Employee Severance [Member] | Q1 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 1,615 | ||||
Diagnostics [Member] | Employee Severance [Member] | Q3 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 901 | ||||
Diagnostics [Member] | Employee Severance [Member] | Q1 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 1,134 | ||||
Diagnostics [Member] | Facility Closing [Member] | Q2 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 0 | ||||
Diagnostics [Member] | Facility Closing [Member] | Q1 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 0 | ||||
Diagnostics [Member] | Facility Closing [Member] | Q3 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 0 | ||||
Diagnostics [Member] | Facility Closing [Member] | Q1 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 682 | ||||
Diagnostics [Member] | Facility Relocation [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | $ 200 | ||||
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q2 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 968 | ||||
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 3,941 | ||||
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q3 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 2,080 | ||||
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 2,312 | ||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | 0 | ||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2021 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | $ 0 | ||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | $ 0 | ||||
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2020 Restructuring Plan [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | $ 92 | ||||
Discovery & Analytical Solutions [Member] | Facility Relocation [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and contract termination charges, net | $ 2,300 | $ 2,500 |
Restructuring and Lease Charg_5
Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) - Q3 2020 Restructuring Plan [Member] $ in Thousands | 3 Months Ended |
Oct. 04, 2020USD ($) | |
Restructuring Reserve [Roll Forward] | |
Restructuring and contract termination charges, net | $ 2,981 |
Diagnostics [Member] | Facility Closing [Member] | |
Restructuring Reserve [Roll Forward] | |
Restructuring and contract termination charges, net | 0 |
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | |
Restructuring Reserve [Roll Forward] | |
Restructuring and contract termination charges, net | $ 0 |
Interest and Other Expense (I_3
Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Other Income and Expenses [Abstract] | ||||
Interest income | $ (367) | $ (192) | $ (778) | $ (457) |
Interest expense | 16,750 | 11,586 | 30,876 | 25,251 |
Loss (Gain) on disposition of businesses and assets, net | 485 | |||
Change in fair value of financial securities | (8,633) | 0 | (27,931) | 0 |
Other expense, net | (1,319) | (582) | (8,442) | (3,989) |
Total interest and other expense, net | 6,431 | 10,812 | (6,275) | 20,805 |
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments | 3,300 | 7,600 | (1,500) | (4,000) |
Foreign Currency Transaction Gain (Loss), before Tax | $ 800 | $ 6,400 | $ (600) | $ (3,500) |
Inventories, Net (Details)
Inventories, Net (Details) - USD ($) $ in Thousands | Jul. 04, 2021 | Jan. 03, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 199,770 | $ 205,022 |
Work in progress | 40,646 | 35,160 |
Finished goods | 273,013 | 274,385 |
Total inventories, net | $ 513,429 | $ 514,567 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Income Tax Contingency [Line Items] | ||||
Share-based Payment Arrangement, Expense | $ 7,204 | $ 9,603 | ||
Provision for income taxes | 80,089 | 27,614 | $ 181,228 | $ 28,588 |
Discontinued Operation, Tax Effect of Discontinued Operation | $ 38 | $ 51 | $ 76 | $ 101 |
Debt (Details)
Debt (Details) | Mar. 08, 2021USD ($) | Jul. 04, 2021USD ($) | Jul. 04, 2021EUR (€) | Jan. 03, 2021USD ($) |
Debt Instrument, Unamortized Discount | $ (5,412,000) | $ (5,765,000) | ||
Unamortized Debt Issuance Expense | (19,459,000) | (12,540,000) | ||
Debt, Long-term and Short-term, Combined Amount | 2,378,063,000 | 2,008,954,000 | ||
Long-term Debt, Gross | 2,373,394,000 | 1,627,761,000 | ||
Current portion of long-term debt | 4,669,000 | 380,948,000 | ||
Significant Other Observable Inputs (Level 2) [Member] | ||||
Long-term Debt | 2,348,523,000 | 1,609,701,000 | ||
Debt, Long-term and Short-term, Combined Amount | 2,353,192,000 | 1,990,649,000 | ||
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | ||||
Debt Instrument, Interest Rate, Stated Percentage | 2.55% | |||
Unsecured senior notes, face value | $ 400,000,000 | |||
Gross proceeds from the issuance of debt instrument | $ 399,900,000 | |||
Senior unsecured notes issuance as percentage of principal amount | 99.965% | |||
Debt Instrument, Unamortized Discount | $ (100,000) | (136,000) | ||
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes | 101.00% | |||
Unamortized Debt Issuance Expense | (3,563,000) | |||
Long-term Debt, Gross | 400,000,000 | |||
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Long-term Debt | $ 396,301,000 | |||
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Treasury Rate [Member] | ||||
Basis spread on variable rate | 0.15% | |||
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | ||||
Debt Instrument, Interest Rate, Stated Percentage | 3.625% | |||
Unsecured senior notes, face value | $ 400,000,000 | |||
Gross proceeds from the issuance of debt instrument | $ 400,000,000 | |||
Senior unsecured notes issuance as percentage of principal amount | 99.999% | |||
Debt Instrument, Unamortized Discount | $ (4,000) | $ (4,000) | ||
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes | 101.00% | |||
Unamortized Debt Issuance Expense | (4,545,000) | |||
Long-term Debt, Gross | 400,000,000 | |||
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Long-term Debt | $ 395,451,000 | |||
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Treasury Rate [Member] | ||||
Basis spread on variable rate | 0.20% | |||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | ||||
Debt Instrument, Unamortized Discount | (16,000) | |||
Unamortized Debt Issuance Expense | (229,000) | |||
Current portion of long-term debt | 366,450,000 | |||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Current portion of long-term debt | 366,205,000 | |||
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | ||||
Debt Instrument, Unamortized Discount | $ (2,368,000) | (2,496,000) | ||
Unamortized Debt Issuance Expense | (6,556,000) | (6,908,000) | ||
Long-term Debt, Gross | 850,000,000 | 850,000,000 | ||
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Long-term Debt | $ 841,076,000 | 840,596,000 | ||
Other Debt Facilities - EUROIMMUN [Member] | ||||
Long-term Debt, Percentage Bearing Variable Interest, Amount | € | € 23,000 | |||
Other Debt Facilities - EUROIMMUN [Member] | Euribor Rate [Member] | ||||
Basis spread on variable rate | 1.50% | |||
Line of Credit, Maturing September 17, 2024 [Member] | ||||
Debt Instrument, Unamortized Discount | $ 0 | 0 | ||
Long-term Debt | 122,736,000 | 155,974,000 | ||
Unamortized Debt Issuance Expense | (2,264,000) | (2,621,000) | ||
Revolving credit facility outstanding balance | 125,000,000 | 158,595,000 | ||
1.875 Percent Ten Year Senior Unsecured Notes [Member] | ||||
Debt Instrument, Unamortized Discount | (2,904,000) | (3,253,000) | ||
Unamortized Debt Issuance Expense | (2,531,000) | (2,782,000) | ||
Long-term Debt, Gross | 592,300,000 | 610,750,000 | ||
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Long-term Debt | 586,865,000 | 604,715,000 | ||
Other Debt Facilities - Current [Member] | ||||
Debt Instrument, Unamortized Discount | 0 | 0 | ||
Other Long-term Debt, Current | 4,669,000 | 14,743,000 | ||
Unamortized Debt Issuance Expense | 0 | 0 | ||
Other Debt Facilities - Current [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Other Long-term Debt, Current | 4,669,000 | 14,743,000 | ||
Other Debt Facilities - Non-current [Member] | ||||
Debt Instrument, Unamortized Discount | 0 | 0 | ||
Other Long-term Debt, Noncurrent | 6,094,000 | 8,416,000 | ||
Unamortized Debt Issuance Expense | 0 | 0 | ||
Other Debt Facilities - Non-current [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||
Other Long-term Debt, Noncurrent | 6,094,000 | 8,416,000 | ||
Other Debt Facilities, excluding the senior revolving credit facility [Member] | ||||
Long-term Debt, Percentage Bearing Fixed Interest, Amount | € | € 10,700,000 | |||
Long-term Debt [Member] | ||||
Debt Instrument, Unamortized Discount | (5,412,000) | (5,749,000) | ||
Unamortized Debt Issuance Expense | $ (19,459,000) | $ (12,311,000) | ||
Minimum [Member] | Other Debt Facilities, excluding the senior revolving credit facility [Member] | ||||
Debt Instrument, Interest Rate, Stated Percentage | 1.10% | 1.10% | ||
Maximum [Member] | Other Debt Facilities, excluding the senior revolving credit facility [Member] | ||||
Debt Instrument, Interest Rate, Stated Percentage | 8.90% | 8.90% |
Earnings Per Share (Schedule of
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Earnings Per Share [Abstract] | ||||
Number of common shares-basic | 111,973 | 111,329 | 112,000 | 111,225 |
Effect of dilutive securities, Stock options | 344 | 470 | 352 | 475 |
Effect of dilutive securities, Restricted stock | 100 | 70 | 104 | 56 |
Number of common shares-diluted | 112,417 | 111,869 | 112,456 | 111,756 |
Number of potentially dilutive securities excluded from calculation due to antidilutive impact | 224 | 390 | 193 | 440 |
Industry Segment Information In
Industry Segment Information Industry Segment Information Narrative (Details) | 3 Months Ended |
Jul. 04, 2021segments | |
Segment Reporting Information [Line Items] | |
Number of Operating Segment | 2 |
Industry Segment Information (S
Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 1,228,471 | $ 811,718 | $ 2,536,160 | $ 1,464,114 |
Operating income (loss) from continuing operations | 332,488 | 175,639 | 800,264 | 220,321 |
Interest and other expense (income), net | 6,431 | 10,812 | (6,275) | 20,805 |
Income from continuing operations before income taxes | 326,057 | 164,827 | 806,539 | 199,516 |
Product [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 767,759 | 601,506 | 1,579,311 | 1,027,035 |
Service [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 460,712 | 210,212 | 956,849 | 437,079 |
Corporate [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Operating income (loss) from continuing operations | (17,947) | (24,091) | (34,585) | (37,513) |
Diagnostics [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 715,642 | 420,716 | 1,568,722 | 674,717 |
Operating income (loss) from continuing operations | 286,280 | 160,300 | 727,747 | 189,891 |
Diagnostics [Member] | Product [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 449,674 | 375,889 | 993,971 | 586,062 |
Diagnostics [Member] | Service [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 265,968 | 44,827 | 574,751 | 88,655 |
Discovery & Analytical Solutions [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 512,829 | 391,002 | 967,438 | 789,397 |
Operating income (loss) from continuing operations | 64,155 | 39,430 | 107,102 | 67,943 |
Discovery & Analytical Solutions [Member] | Product [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 318,085 | 225,617 | 585,340 | 440,973 |
Discovery & Analytical Solutions [Member] | Service [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 194,744 | $ 165,385 | $ 382,098 | $ 348,424 |
Stockholders' Equity (Narrative
Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended | ||||||
Oct. 03, 2021 | Jul. 04, 2021 | Apr. 04, 2021 | Jan. 03, 2021 | Oct. 04, 2020 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 23, 2018 | |
Schedule of Shareholders' Equity [Line Items] | ||||||||
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans | 8,622 | 70,413 | ||||||
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans | $ 1.2 | $ 10.3 | ||||||
Cash dividends (per share) | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | $ 0.07 | ||
Dividends Payable, Amount | $ 7.9 | $ 7.9 | ||||||
Dividends Payable, Date Declared | Apr. 29, 2021 | |||||||
Repurchase Program, 07/31/2020 [Member] | ||||||||
Schedule of Shareholders' Equity [Line Items] | ||||||||
Stock Repurchase Program, Authorized Amount | $ 250 | |||||||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 187.4 | $ 187.4 | ||||||
Number of common stock repurchased in open market | 200,000 | 433,000 | ||||||
Aggregate Cost of Repurchased Common Shares Under Repurchase Program | $ 29 | $ 62.6 | ||||||
Subsequent Event [Member] | ||||||||
Schedule of Shareholders' Equity [Line Items] | ||||||||
Cash dividends (per share) | $ 0.07 | |||||||
Dividends Payable, Date Declared | Jul. 23, 2021 |
Stockholders' Equity (Component
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands | Jul. 04, 2021 | Jan. 03, 2021 |
Stockholders' Equity Note [Abstract] | ||
Foreign currency translation adjustments, net of income taxes | $ (91,518) | $ (30,937) |
Unrecognized losses and prior service costs, net of income taxes | (747) | (747) |
Unrealized net losses on securities, net of income taxes | (172) | (277) |
Accumulated other comprehensive loss | $ (92,437) | $ (31,961) |
Stock Plans (Narrative) (Detail
Stock Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | Jan. 03, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Total income tax benefit recognized for stock-based compensation | $ 4,100 | $ 2,200 | |||
Stock-based compensation costs capitalized as part of inventory | $ 500 | $ 300 | |||
Proceeds from issuance of common stock under stock plans | $ 14,185 | $ 10,074 | |||
Share-based Payment Arrangement, Expense | 7,204 | 9,603 | |||
Stock Options [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Weighted-average grant-date fair value of options | $ 65.80 | $ 18.98 | |||
Total intrinsic value of options exercised | 9,500 | 7,800 | |||
Proceeds from issuance of common stock under stock plans | $ 5,000 | $ 1,100 | |||
Share-based Payment Arrangement, Expense | 900 | 800 | |||
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | 8,900 | $ 8,900 | |||
Weighted-average period for recognition of unrecognized compensation cost, years | 2 years 3 months 18 days | ||||
Restricted Stock Awards [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Payment Arrangement, Expense | 2,800 | 2,700 | |||
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | $ 23,400 | $ 23,400 | |||
Weighted-average period for recognition of unrecognized compensation cost, years | 1 year 9 months 18 days | ||||
Awards/units outstanding | 291,000 | 291,000 | 296,000 | ||
Number of Shares, Granted | 102,000 | ||||
Weighted-average grant-date fair value of stock granted (per share) | $ 129.27 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 5,000 | ||||
Fair value of restricted stock awards vested | $ 8,500 | 1,400 | |||
Performance Units [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Payment Arrangement, Expense | $ 100 | 3,300 | |||
Awards/units outstanding | 0 | 0 | |||
Number of Shares, Granted | 0 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 0 | ||||
Stock Awards [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of Shares, Granted | 0 | ||||
Employee Stock Purchase Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares authorized under plan | 5,000,000 | 5,000,000 | |||
Number of Shares, Granted | 58 | 13,612 | |||
Weighted-average grant-date fair value of stock granted (per share) | $ 136.33 | $ 92.25 | |||
Shares available for grant under employee stock purchase plan | 800,000 | 800,000 | |||
Performance Restricted Stock Units [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Share-based Payment Arrangement, Expense | $ 1,400 | $ 2,000 | |||
Awards/units outstanding | 128,386 | 128,386 | |||
Number of Shares, Granted | 77,373 | ||||
Weighted-average grant-date fair value of stock granted (per share) | $ 113.44 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 0 |
Stock Plans (Summary of Total C
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 04, 2021 | Jul. 05, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Payment Arrangement, Expense | $ 7,204 | $ 9,603 |
Cost of sales [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Payment Arrangement, Expense | 692 | 253 |
Research and development expenses [Member ] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Payment Arrangement, Expense | 366 | 316 |
Selling, general and administrative and other expenses [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based Payment Arrangement, Expense | $ 6,146 | $ 9,034 |
Stock Plans (Weighted-Average A
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details) | 6 Months Ended | |
Jul. 04, 2021 | Jul. 05, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Risk-free interest rate | 0.60% | 0.90% |
Expected dividend yield | 0.20% | 0.30% |
Expected lives, years | 5 years | 5 years |
Expected stock volatility | 27.30% | 23.80% |
Stock Plans (Summary of Stock O
Stock Plans (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 6 Months Ended | |
Jul. 04, 2021 | Jul. 05, 2020 | |
Stock option activity | ||
Number of Shares, Outstanding at beginning of period | 961 | |
Number of Shares, Granted | 162 | |
Number of Shares, Exercised | (96) | |
Number of Shares, Forfeited | (7) | |
Number of Shares, Outstanding at end of period | 1,020 | |
Number of Shares, Exercisable at end of period | 640 | |
Weighted-Average Price, Outstanding at beginning of period | $ 74.40 | |
Weighted-Average Price, Granted | 134.53 | |
Weighted-Average Price, Exercised | 53.98 | |
Weighted-Average Price, Forfeited | 88.54 | |
Weighted-Average Price, Outstanding at end of period | 85.78 | |
Weighted-Average Price, Exercisable at end of period | $ 72.63 | |
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period | 4 years 3 months 18 days | |
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period | 3 years 2 months 12 days | |
Total Intrinsic Value, Outstanding at end of period | $ 46.2 | |
Total Intrinsic Value, Exercisable at end of period | 36.7 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||
Stock-based compensation costs capitalized as part of inventory | $ 0.5 | $ 0.3 |
Stock Plans (Summary of Restric
Stock Plans (Summary of Restricted Stock Award Activity) (Details) - Restricted Stock Awards [Member] shares in Thousands | 6 Months Ended |
Jul. 04, 2021$ / sharesshares | |
Restricted stock award activity | |
Number of Shares, Nonvested at beginning of period | shares | 296 |
Number of Shares, Granted | shares | 102 |
Number of Shares, Vested | shares | (102) |
Number of Shares, Forfeited | shares | (5) |
Number of Shares, Nonvested at end of period | shares | 291 |
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period | $ / shares | $ 85.67 |
Weighted-Average Grant-Date Fair Value, Granted | $ / shares | 129.27 |
Weighted-Average Grant-Date Fair Value, Vested | $ / shares | 83.16 |
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares | 86.90 |
Weighted-Average Grant-Date Fair Value, Nonvested at end of period | $ / shares | $ 101.83 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands | Jan. 04, 2021 | Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | Jan. 03, 2021 |
Goodwill and Intangible Assets Net [Line Items] | ||||||
Change in any one of the input assumptions for the various reporting units | 10.00% | |||||
Goodwill | $ 3,844,070 | $ 3,844,070 | $ 3,447,114 | |||
Total amortization expense related to finite-lived intangible assets | 59,600 | $ 46,700 | 113,700 | $ 94,000 | ||
Future Amortization Expense, Remainder of Fiscal Year | 116,800 | 116,800 | ||||
Future Amortization Expense, Year One | 224,200 | 224,200 | ||||
Future Amortization Expense, Year Two | 200,900 | 200,900 | ||||
Future Amortization Expense, Year Three | 180,100 | 180,100 | ||||
Future Amortization Expense, Year Four | 151,300 | 151,300 | ||||
Finite-Lived Intangible Assets, Net | 1,490,950 | 1,490,950 | 1,295,109 | |||
Intangible assets, net | 1,561,534 | 1,561,534 | 1,365,693 | |||
Minimum [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Long-term terminal growth rates for reporting units | 3.00% | |||||
Discount rates for reporting units | 8.00% | |||||
Maximum [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Long-term terminal growth rates for reporting units | 5.00% | |||||
Discount rates for reporting units | 12.50% | |||||
Patents [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Gross amortizable intangible assets | 31,042 | 31,042 | 30,855 | |||
Less: Accumulated amortization | 28,590 | 28,590 | 28,440 | |||
Finite-Lived Intangible Assets, Net | 2,452 | 2,452 | 2,415 | |||
Trade Names And Trademarks [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Gross amortizable intangible assets | 122,959 | 122,959 | 98,661 | |||
Less: Accumulated amortization | 54,468 | 54,468 | 48,806 | |||
Finite-Lived Intangible Assets, Net | 68,491 | 68,491 | 49,855 | |||
Licensing Agreements [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Gross amortizable intangible assets | 59,015 | 59,015 | 58,700 | |||
Less: Accumulated amortization | 53,391 | 53,391 | 52,452 | |||
Finite-Lived Intangible Assets, Net | 5,624 | 5,624 | 6,248 | |||
Core Technology [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Gross amortizable intangible assets | 980,388 | 980,388 | 789,799 | |||
Less: Accumulated amortization | 435,709 | 435,709 | 398,992 | |||
Finite-Lived Intangible Assets, Net | 544,679 | 544,679 | 390,807 | |||
Customer Relationships [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Gross amortizable intangible assets | 1,441,419 | 1,441,419 | 1,357,660 | |||
Less: Accumulated amortization | 582,624 | 582,624 | 522,820 | |||
Finite-Lived Intangible Assets, Net | 858,795 | 858,795 | 834,840 | |||
In-process Research and Development [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Gross amortizable intangible assets | $ 10,909 | $ 10,909 | $ 10,944 | |||
Tulip Diagnostics Private Limited [Member] | ||||||
Goodwill and Intangible Assets Net [Line Items] | ||||||
Goodwill | $ 77,800 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands | 6 Months Ended |
Jul. 04, 2021USD ($) | |
Changes in the carrying amount of goodwill | |
Balance at beginning of period | $ 3,447,114 |
Foreign currency translation | (36,957) |
Goodwill, Acquisition, Earn Outs and Other Adjustments | 433,913 |
Balance at end of period | 3,844,070 |
Diagnostics [Member] | |
Changes in the carrying amount of goodwill | |
Balance at beginning of period | 1,691,227 |
Foreign currency translation | (17,806) |
Goodwill, Acquisition, Earn Outs and Other Adjustments | 278,714 |
Balance at end of period | 1,952,135 |
Discovery & Analytical Solutions [Member] | |
Changes in the carrying amount of goodwill | |
Balance at beginning of period | 1,755,887 |
Foreign currency translation | (19,151) |
Goodwill, Acquisition, Earn Outs and Other Adjustments | 155,199 |
Balance at end of period | $ 1,891,935 |
Goodwill and Intangible Asset_5
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands | Jul. 04, 2021 | Jan. 03, 2021 |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Net amortizable intangible assets | $ 1,490,950 | $ 1,295,109 |
Intangible assets, net | 1,561,534 | 1,365,693 |
Patents [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 31,042 | 30,855 |
Less: Accumulated amortization | (28,590) | (28,440) |
Net amortizable intangible assets | 2,452 | 2,415 |
Trade Names And Trademarks [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 122,959 | 98,661 |
Less: Accumulated amortization | (54,468) | (48,806) |
Net amortizable intangible assets | 68,491 | 49,855 |
Trade names and trademarks | 70,584 | 70,584 |
Licensing Agreements [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 59,015 | 58,700 |
Less: Accumulated amortization | (53,391) | (52,452) |
Net amortizable intangible assets | 5,624 | 6,248 |
Core Technology [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 980,388 | 789,799 |
Less: Accumulated amortization | (435,709) | (398,992) |
Net amortizable intangible assets | 544,679 | 390,807 |
Customer Relationships [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | 1,441,419 | 1,357,660 |
Less: Accumulated amortization | (582,624) | (522,820) |
Net amortizable intangible assets | 858,795 | 834,840 |
In-process Research and Development [Member] | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ||
Gross amortizable intangible assets | $ 10,909 | $ 10,944 |
Warranty Reserves (Details)
Warranty Reserves (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Jul. 04, 2021 | Jul. 05, 2020 | |
Warranty reserve activity | ||
Balance beginning of period | $ 12,073 | $ 8,812 |
Provision charged to income | 3,691 | 2,712 |
Payments | (6,182) | (3,266) |
Adjustments to previously provided warranties, net | 2,455 | 1,052 |
Foreign currency translation and acquisitions | (190) | (269) |
Balance end of period | $ 11,847 | $ 9,041 |
Employee Benefit Plans (Compone
Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | |
Defined Benefit Pension Benefits [Member] | ||||
Components of net periodic benefit cost (credit) | ||||
Service cost | $ 1,338 | $ 1,688 | $ 2,672 | $ 3,595 |
Interest cost | 2,376 | 3,138 | 4,753 | 6,282 |
Expected return on plan assets | (6,121) | (5,371) | (12,248) | (10,755) |
Net periodic benefit cost (credit) | (2,407) | (545) | (4,823) | (878) |
Postretirement Medical Benefits [Member] | ||||
Components of net periodic benefit cost (credit) | ||||
Service cost | 15 | 18 | 29 | 36 |
Interest cost | 17 | 23 | 34 | 47 |
Expected return on plan assets | (397) | (347) | (794) | (694) |
Net periodic benefit cost (credit) | $ (365) | $ (306) | (731) | (611) |
UNITED STATES | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Plan Assets, Contributions by Employer | 20,000 | |||
Foreign Plan [Member] | ||||
Defined Benefit Plan Disclosure [Line Items] | ||||
Defined Benefit Plan, Plan Assets, Contributions by Employer | $ 3,700 | $ 3,400 |
Derivatives And Hedging Activ_2
Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions | 3 Months Ended | 6 Months Ended | ||||||
Jul. 04, 2021USD ($) | Jul. 05, 2020USD ($) | Jul. 04, 2021USD ($) | Jul. 04, 2021EUR (€) | Jul. 05, 2020USD ($) | Jan. 03, 2021USD ($) | Jan. 03, 2021EUR (€) | Jul. 05, 2020EUR (€) | |
Derivative [Line Items] | ||||||||
Company's business conducted outside United States | 70.00% | 70.00% | ||||||
Payments for (Proceeds from) Hedge, Financing Activities | $ 5,935 | $ (5,037) | ||||||
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net | $ 0 | 0 | ||||||
Foreign Currency Transaction Gain (Loss), before Tax | 800 | $ 6,400 | $ (600) | (3,500) | ||||
European And Asian Currencies [Member] | ||||||||
Derivative [Line Items] | ||||||||
Maximum maturity period for foreign exchange contracts, in months | 12 months | 12 months | ||||||
Duration Of Foreign Currency Derivatives | 30 days | 30 days | ||||||
Cash Flow Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member] | ||||||||
Derivative [Line Items] | ||||||||
Unrealized Gain (Loss) on Derivatives | (1,700) | $ (800) | ||||||
Derivative, Notional Amount | 197,400 | 197,400 | ||||||
Cash Flow Hedging [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | ||||||||
Derivative [Line Items] | ||||||||
Unrealized Gain (Loss) on Derivatives | (4,100) | 9,500 | (3,800) | |||||
Fair Value Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | 444,700 | 358,700 | 444,700 | 358,700 | $ 808,000 | |||
Notional Amount of Euro Derivatives [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | € | € 33.4 | € 104.8 | ||||||
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Notional Amount | 309,400 | 267,000 | 309,400 | 267,000 | $ 499,000 | |||
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member] | ||||||||
Derivative [Line Items] | ||||||||
Notional Amount of Nonderivative Instruments | € | € 299.7 | |||||||
Unrealized Gain (Loss) on Net Investment Hedge in AOCI | $ (2,500) | $ (22,300) | $ 19,100 | $ (1,300) | ||||
United States of America, Dollars | Cross-currency Swap [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Fixed Interest Rate | 5.00% | 5.00% | ||||||
United States of America, Dollars | Net Investment Hedging [Member] | Cross-currency Swap [Member] | ||||||||
Derivative [Line Items] | ||||||||
Notional Amount of Nonderivative Instruments | $ 220,000 | |||||||
Fair Value of Cross-currency Swap | $ (13,000) | $ (13,000) | ||||||
Euro Member Countries, Euro | Cross-currency Swap [Member] | ||||||||
Derivative [Line Items] | ||||||||
Derivative, Fixed Interest Rate | 2.47% | 2.47% | ||||||
Euro Member Countries, Euro | Net Investment Hedging [Member] | Cross-currency Swap [Member] | ||||||||
Derivative [Line Items] | ||||||||
Notional Amount of Nonderivative Instruments | $ 197,400 |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) € in Millions | 6 Months Ended | ||||||||
Jul. 04, 2021USD ($) | Jul. 05, 2020USD ($) | Jul. 04, 2021EUR (€) | Apr. 04, 2021USD ($) | Mar. 08, 2021USD ($) | Jan. 03, 2021USD ($) | Jan. 03, 2021EUR (€) | Apr. 05, 2020USD ($) | Dec. 29, 2019USD ($) | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 3,334,000 | $ 13,726,000 | $ 3,124,000 | $ 2,953,000 | $ 22,777,000 | $ 35,481,000 | |||
Unamortized Debt Issuance Expense | 19,459,000 | 12,540,000 | |||||||
Debt Instrument, Unamortized Discount | (5,412,000) | (5,765,000) | |||||||
Payments for acquisition related contingent consideration | 0 | $ (5,200,000) | |||||||
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Unamortized Debt Issuance Expense | 3,563,000 | ||||||||
Unsecured senior notes, face value | $ 400,000,000 | ||||||||
Debt Instrument, Unamortized Discount | (136,000) | (100,000) | |||||||
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Unamortized Debt Issuance Expense | 4,545,000 | ||||||||
Unsecured senior notes, face value | 400,000,000 | ||||||||
Debt Instrument, Unamortized Discount | (4,000) | $ (4,000) | |||||||
Line of Credit, Maturing September 17, 2024 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Revolving credit facility outstanding balance | 125,000,000 | 158,595,000 | |||||||
Unamortized Debt Issuance Expense | 2,264,000 | 2,621,000 | |||||||
Long-term Debt | 122,736,000 | 155,974,000 | |||||||
Debt Instrument, Unamortized Discount | 0 | 0 | |||||||
1.875 Percent Ten Year Senior Unsecured Notes [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Unamortized Debt Issuance Expense | 2,531,000 | 2,782,000 | |||||||
Debt Instrument, Unamortized Discount | (2,904,000) | (3,253,000) | |||||||
0.6 Percent Senior Unsecured Notes due in April 2021 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Unamortized Debt Issuance Expense | 229,000 | ||||||||
Debt Instrument, Unamortized Discount | (16,000) | ||||||||
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Unamortized Debt Issuance Expense | 6,556,000 | 6,908,000 | |||||||
Debt Instrument, Unamortized Discount | (2,368,000) | (2,496,000) | |||||||
Senior Unsecured Notes [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Unsecured senior notes, fair value | 2,411,600,000 | 1,984,300,000 | |||||||
Other Debt Facilities, excluding the senior revolving credit facility [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt, Percentage Bearing Fixed Interest, Amount | € | € 10.7 | ||||||||
DNA Labs & Biosense [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 7,200,000 | ||||||||
Business Combination, Contingent Consideration Arrangements, Description | Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. | ||||||||
Business Combination, Contingent Consideration Arrangements, Maximum Period | 1 year 6 months | ||||||||
Business Combination, Contingent Consideration Arrangements, Weighted Average Period | 9 months 18 days | ||||||||
Significant Other Observable Inputs (Level 2) [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt | $ 2,348,523,000 | 1,609,701,000 | |||||||
Significant Other Observable Inputs (Level 2) [Member] | 2.55 Percent Senior Unsecured Notes due in 2031 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt | 396,301,000 | ||||||||
Significant Other Observable Inputs (Level 2) [Member] | 3.625 Percent Senior Unsecured Notes due in 2051 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt | 395,451,000 | ||||||||
Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt | 586,865,000 | 604,715,000 | |||||||
Significant Other Observable Inputs (Level 2) [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt | 841,076,000 | 840,596,000 | |||||||
Significant Other Observable Inputs (Level 2) [Member] | Senior Unsecured Notes [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Long-term Debt | $ 2,219,700,000 | $ 1,811,500,000 | |||||||
Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities, including the senior revolving credit facility [Member] | |||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||||||
Other Long-term Debt | € | € 133.5 | € 179.1 |
Fair Value Measurements (Assets
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands | Jul. 04, 2021 | Apr. 04, 2021 | Jan. 03, 2021 | Jul. 05, 2020 | Apr. 05, 2020 | Dec. 29, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 3,334 | $ 3,124 | $ 2,953 | $ 13,726 | $ 22,777 | $ 35,481 |
Fair Value, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member] | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Marketable securities | 50,100 | 2,154 | ||||
Foreign exchange derivative assets, net | (2,663) | (31,248) | ||||
Foreign exchange derivative liabilities, net | (13,670) | (21,413) | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 3,334 | 2,953 | ||||
Fair Value, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member] | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Marketable securities | 50,100 | 2,154 | ||||
Foreign exchange derivative assets, net | 0 | 0 | ||||
Foreign exchange derivative liabilities, net | 0 | 0 | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 0 | 0 | ||||
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member] | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Marketable securities | 0 | 0 | ||||
Foreign exchange derivative assets, net | (2,663) | (31,248) | ||||
Foreign exchange derivative liabilities, net | (13,670) | (21,413) | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | 0 | 0 | ||||
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member] | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Marketable securities | 0 | 0 | ||||
Foreign exchange derivative assets, net | 0 | 0 | ||||
Foreign exchange derivative liabilities, net | 0 | 0 | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 3,334 | $ 2,953 |
Fair Value Measurements (Reconc
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jul. 04, 2021 | Jul. 05, 2020 | Jul. 04, 2021 | Jul. 05, 2020 | Jan. 03, 2021 | |
Fair Value Disclosures [Abstract] | |||||
Balance beginning of period | $ (3,124) | $ (22,777) | $ (2,953) | $ (35,481) | |
Payments | 27 | 9,930 | 96 | 10,309 | |
Change in fair value (included within selling, general and administrative expenses) | (237) | (879) | (477) | 11,446 | |
Balance end of period | (3,334) | $ (13,726) | (3,334) | $ (13,726) | |
Business Combination, Contingent Consideration, Liability | $ (3,300) | $ (3,300) | $ (3,000) |
Contingencies (Details)
Contingencies (Details) $ in Millions | 6 Months Ended | |
Jul. 04, 2021USD ($)years | Jan. 03, 2021USD ($) | |
Commitments and Contingencies Disclosure [Abstract] | ||
Management's estimate of total cost of ultimate disposition | $ | $ 12.1 | $ 12.9 |
Number of years over which estimated environmental cost will be paid | years | 10 |